<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomol Ther (Seoul)</journal-id><journal-id journal-id-type="iso-abbrev">Biomol Ther (Seoul)</journal-id><journal-id journal-id-type="publisher-id">Biomol Ther (Seoul)</journal-id><journal-id journal-id-type="publisher-id">ksp</journal-id><journal-title-group><journal-title>Biomolecules &#x00026; Therapeutics</journal-title></journal-title-group><issn pub-type="ppub">1976-9148</issn><issn pub-type="epub">2005-4483</issn><publisher><publisher-name>The Korean Society of Applied Pharmacology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5012869</article-id><article-id pub-id-type="pmid">27582553</article-id><article-id pub-id-type="doi">10.4062/biomolther.2016.168</article-id><article-id pub-id-type="publisher-id">bt-24-453</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Proposal of Dual Inhibitor Targeting ATPase Domains of Topoisomerase II and Heat Shock Protein 90</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jun</surname><given-names>Kyu-Yeon</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kwon</surname><given-names>Youngjoo</given-names></name><xref rid="c1-bt-24-453" ref-type="corresp"><sup>*</sup></xref></contrib><aff id="af1-bt-24-453">College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, 
<country>Republic of Korea</country></aff></contrib-group><author-notes><corresp id="c1-bt-24-453"><label>*</label>Corresponding Author: E-mail: <email>ykwon@ewha.ac.kr</email>, Tel: +82-2-3277-4653, Fax: +82-2-3277-3051</corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>01</day><month>9</month><year>2016</year></pub-date><volume>24</volume><issue>5</issue><fpage>453</fpage><lpage>468</lpage><history><date date-type="received"><day>02</day><month>8</month><year>2016</year></date><date date-type="rev-recd"><day>11</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>16</day><month>8</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2016, The Korean Society of Applied Pharmacology</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>There is a conserved ATPase domain in topoisomerase II (topo II) and heat shock protein 90 (Hsp90) which belong to the GHKL (gyrase, Hsp90, histidine kinase, and MutL) family. The inhibitors that target each of topo II and Hsp90 are intensively studied as anti-cancer drugs since they play very important roles in cell proliferation and survival. Therefore the development of dual targeting anti-cancer drugs for topo II and Hsp90 is suggested to be a promising area. The topo II and Hsp90 inhibitors, known to bind to their ATP binding site, were searched. All the inhibitors investigated were docked to both topo II and Hsp90. Four candidate compounds as possible dual inhibitors were selected by analyzing the molecular docking study. The pharmacophore model of dual inhibitors for topo II and Hsp90 were generated and the design of novel dual inhibitor was proposed.</p></abstract><kwd-group><kwd>Topoisomerase II</kwd><kwd>Heat shock protein 90</kwd><kwd>Molecular docking study</kwd><kwd>Design of dual inhibitor</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Topoisomerase II (topo II) and heat shock protein 90 (Hsp90) both contain a conserved ATPase domain and belong to the same family, namely, GHKL (gyrase, Hsp90, histidine kinase, and MutL) domain (<xref rid="b10-bt-24-453" ref-type="bibr">Dutta and Inouye, 2000</xref>; <xref rid="b6-bt-24-453" ref-type="bibr">Chene, 2002</xref>). ATPase domain in both of these proteins requires ATP to exert important cellular functions such as cell cycle progression, proliferation and survival. Therefore, inhibitors targeting the ATP binding site of these two proteins through binding in an ATP-competitive manner were searched and characterized in this study. Another important biological implication in topo II and Hsp90 is that they are both overexpressed in proliferating cancer cells and have been attractive targets for the development of anti-cancer drugs (<xref rid="b33-bt-24-453" ref-type="bibr">Neckers, 2002</xref>; <xref rid="b34-bt-24-453" ref-type="bibr">Nitiss, 2009a</xref>).</p><p>Topo II is very important in cellular processes such as transcription and replication by introducing transient breaks in DNA double strand (<xref rid="b35-bt-24-453" ref-type="bibr">Nitiss, 2009b</xref>). Topo II requires ATP binding for its conformational change to solve topological problems in DNA. Recently, there are much efforts in developing catalytic inhibitors of topo II in order to overcome the side-effects of topo II poisons such as etoposide (<xref rid="b39-bt-24-453" ref-type="bibr">Pogorelcnik <italic>et al</italic>., 2013</xref>). Hsp90 is a molecular chaperone which has diverse client proteins involved in tumor growth and survival. Therefore, Hsp90 also has been an attractive target for chemotherapeutic development and phase II clinical trial was conducted for Hsp90 inhibitor, 17-allyaminogeldanamycin (17-AAG) (<xref rid="b45-bt-24-453" ref-type="bibr">Sidera and Patsavoudi, 2014</xref>). In 2006, Jenkins and coworkers reported that the topo II and Hsp90 form a complex, and co-treatment of 17-AAG showed synergistic efficacy by enhancing the activity of topo II poison (<xref rid="b2-bt-24-453" ref-type="bibr">Barker <italic>et al</italic>., 2006</xref>; <xref rid="b54-bt-24-453" ref-type="bibr">Yao <italic>et al</italic>., 2007</xref>). From these findings, development of inhibitors that target both ATPase domains of topo II and Hsp90 can be a promising research area. There are many advantages of multi-target drugs since they can simultaneously inhibit multiple pathways and escape an undesirable drug-drug interaction which may encounter with co-treatment of single-target drugs (<xref rid="b38-bt-24-453" ref-type="bibr">Petrelli and Giordano, 2008</xref>).</p><p>In this review, the topo II and Hsp90 inhibitors that bind to the ATPase domain of each of topo II and Hsp90 are analyzed and the possibility of designing dual inhibitor is explored through molecular modelling studies.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Molecular docking studies</title><p>The 3D structures of the inhibitors of topo II and Hsp90 were sketched using Sybyl X-2.1.1 (Certara L.P., St. Louis, MO, USA). All the structures were energetically minimized using Tripos force field and Gasteiger-H&#x000fc;ckel charges. The structures of ATPase domain of topo II and Hsp90 were retrieved from RCSB Protein Data Bank (PDB entry code: 1ZXM and 3EKR) (<xref rid="b50-bt-24-453" ref-type="bibr">Wei <italic>et al</italic>., 2005</xref>; <xref rid="b25-bt-24-453" ref-type="bibr">Kung <italic>et al</italic>., 2008</xref>). The ligands were extracted and water molecules were removed from the initial x-ray crystal structure. The docking was carried out for both of the topo II and Hsp90 inhibitors to topo II and Hsp90 using Surflex-Dock (<xref rid="b17-bt-24-453" ref-type="bibr">Jain, 2003</xref>). The protomol was generated using ligand mode, which used the ligand, extracted from the crystal structure occupying the ATP binding site, to ensure that the inhibitor could bind to the ATP binding site. Then polar hydrogens were added to the structure. After the protomol generation, ligands were docked using Surflex-Dock Geom and GeomX modes using default parameters.</p></sec><sec><title>Pharmacophore hypothesis generation</title><p>Compounds PU3, 3t, AUY922 and comp. 14 were used as input molecules to generate pharmacophore model using GASP module implemented in Sybyl X-2.1.1. Four molecules selected were used as the data set for the pharmacophore model generations. All the features on each of the molecules were used and the default GA parameters were used. The parameters used for the calculations were as follows; 100 population size, 1.1 selection pressure, 100000 max operations, 6500 operation increment and 0.01 fitness.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Comparison of the structural similarities of ATPase domain of topo II and Hsp90</title><p>Among structures of ATPase domain of topo II and Hsp90 deposited in Protein Data Bank (PDB), 1ZXM for topo II and 3EKR and 1BYQ for Hsp90 were chosen for structure comparison and docking. The length of the two proteins is 376 and 217 amino acid residues for topo II and Hsp90, respectively. The similarity of the two proteins were compared by sequence alignment using BioEdit (<xref rid="f1-bt-24-453" ref-type="fig">Fig. 1</xref>) (<xref rid="b13-bt-24-453" ref-type="bibr">Hall, 1999</xref>). Although the sequence identity between the two ATPase domains is 15.8 %, which is rather small value, the overall fold has high similarity where they are superimposable (<xref rid="f2-bt-24-453" ref-type="fig">Fig. 2</xref>).</p><p>The ATP binding sites of the two proteins can be suggested to have similar environment. The amino acid residues involved in binding with the ligand adenylyl-imidophosphate (AMPPNP) or ADP for topo II and Hsp90, respectively, do not coincide exactly, however the properties of each amino acids are conserved. For example, in topo II, Asn120 forms hydrogen bond with the N6 amino group of adenine ring, whereas in Hsp90, Asp93 is involved in the hydrogen bond interaction. The hydrophobic residue Ile125 in topo II corresponds to the residue of Met98 in Hsp90 which is also hydrophobic. Additionally, the size of the ATP binding site of each protein was calculated with Computed Atlas of Surface Topography of proteins (CASTp, <ext-link ext-link-type="uri" xlink:href="http://sts.bioe.uic.edu/castp/">http://sts.bioe.uic.edu/castp/</ext-link>) (<xref rid="b28-bt-24-453" ref-type="bibr">Liang <italic>et al</italic>., 1998</xref>). As listed in <xref rid="t1-bt-24-453" ref-type="table">Table 1</xref> and shown in <xref rid="f3-bt-24-453" ref-type="fig">Fig. 3</xref>, the calculated area and volume of topo II ATP binding site were 792.2 &#x000c5;<sup>2</sup> and 1077.6 &#x000c5;<sup>3</sup>, respectively. The ATP binding site&#x02019;s area and volume of Hsp90 were slightly smaller than topo II, 628.9 &#x000c5;<sup>2</sup> and 971.0 &#x000c5;<sup>3</sup>, respectively. The mouth opening of the binding pocket was also identified and characterized with CASTp. Although the overall pocket size was slightly larger for topo II, the area and the circumcircle of the mouth opening of Hsp90 were larger than topo II, with the values of 167.6 &#x000c5;<sup>2</sup>, 78.6 &#x000c5; and 70.9 &#x000c5;<sup>2</sup>, 52.6 &#x000c5;, respectively.</p></sec><sec><title>Topo II inhibitors that bind to the ATPase domain</title><p>The topo II inhibitors that bind to the topo II ATPase domain were searched. The inhibitors can be largely divided into two categories, purine analogues and non-purine analogues. <xref rid="t2-bt-24-453" ref-type="table">Table 2</xref> lists the topo II inhibitors and gives information about their structures and ATPase inhibition activity where applicable.</p><p>Purine analogue inhibitors contain the purine ring and have substitutions on the 2, 6, or 9 positions. In order to develop novel topo II catalytic inhibitors, 1,990 compounds from the National Cancer Institute (NCI) diversity set library was screened and <italic>S<sup>6</sup></italic>-substituted thioguanine analog, NSC35866 was identified (<xref rid="b19-bt-24-453" ref-type="bibr">Jensen <italic>et al</italic>., 2005</xref>). This finding was further expanded to discover more potent ATPase inhibitors by screening 40 substituted purine or purine-like compounds in the NCI database and several compounds including NSC348400 were identified from this screening (<xref rid="b18-bt-24-453" ref-type="bibr">Jensen <italic>et al</italic>., 2006</xref>). Compounds 1 and 2 were searched from the Novartis compound collection to specifically target the ATP binding site of topo II (<xref rid="b11-bt-24-453" ref-type="bibr">Furet <italic>et al</italic>., 2009</xref>). The hydrogen bond forming residues of topo II were Asn120 and Asn91 which were identical in three topo II complexes with compounds 1, 2 and AMPPNP, however the purine ring of compounds 1 and 2 adopted different orientation compared to that of ATP. Compounds 1 and 2 were further optimized by considering these interactions with the binding site and obtained a purine analogue with substitution of an ethyl group at position C6 and a morpholino-ethoxy group in the quinolone substituted on position N<sup>2</sup> (called quinoline amino-purine, QAP1) (<xref rid="b7-bt-24-453" ref-type="bibr">Chene <italic>et al</italic>., 2009</xref>). QAP1 showed improvement in topo II ATPase inhibitory activity with the half maximal inhibitory concentration (IC<sub>50</sub>) of 128 &#x000b1; 21 nM. 3t has a new scaffold, aloisine moiety, which is similar to purine ring (<xref rid="b26-bt-24-453" ref-type="bibr">Li <italic>et al</italic>., 2016</xref>). In contrast to compounds 1 and 2, the aloisine ring was aligned with the purine ring of ATP from docking study. 2c is a organoplatinum(II) complex with an attachment of 2-amino-6-chloropurine (<xref rid="b49-bt-24-453" ref-type="bibr">Wang <italic>et al</italic>., 2010</xref>). 2c inhibited topo II by preventing ATP entering into the ATPase domain. Although 2c is a purine analog, its purine moiety did not occupy the ATP purine ring binding site, but the <italic>tert</italic>-butyl groups of the terpyridine scaffold occupied on it, determined by molecular docking study. 8-chloro-adenosine (8-Cl-Ado) is an anti-cancer agent currently undergoing phase I/II clinical trial. 8-Cl-Ado converted into 8-Cl-ATP in cells and it competed with ATP to inhibit topo II (<xref rid="b52-bt-24-453" ref-type="bibr">Yang <italic>et al</italic>., 2009</xref>).</p><p>There are some topo II inhibitors originated from natural products. Daurinol is a lignan isolated from <italic>Haplophyllum dauricum</italic>, whose structure is similar to etoposide (<xref rid="b23-bt-24-453" ref-type="bibr">Kang <italic>et al</italic>., 2014</xref>). Etoposide is a well-known cytotoxic anti-cancer drug functioning as a topo II poison. Daurinol occupied the same binding site with AMPPNP, which was shown by molecular docking study, suggesting it inhibited topo II by targeting the ATPase domain. Gambogic acid (GA) is a natural product isolated from <italic>Garcinia hanburi</italic> tree. GA was shown to be a catalytic inhibitor of topo II by binding to the ATPase domain, determined by surface plasmon resonance (SPR) analysis and by molecular docking (<xref rid="b41-bt-24-453" ref-type="bibr">Qin <italic>et al</italic>., 2007</xref>). Diphyllin was extracted from <italic>Justicia procumbens</italic>, which showed tumoricidal effects. D11 is a novel acetylated D-quinovose diphyllin analogue exhibiting potent topo II inhibitory activity and binding to the ATPase domain (<xref rid="b12-bt-24-453" ref-type="bibr">Gui <italic>et al</italic>., 2011</xref>). When the compound binds to the ATP binding site it is not always a topo II catalytic inhibitor, as it is the case with salvicine and emodin. Salvicine is a derivative of diterpenequinone isolated from <italic>Salvia prionitis</italic>, which bound to the ATPase domain validated by SPR and molecular docking, and acted as a topo II poison generating double strand breaks (<xref rid="b14-bt-24-453" ref-type="bibr">Hu <italic>et al</italic>., 2006</xref>). Emodin is an anthraquinone isolated from <italic>Rheum emodi</italic> and also from molds, lichens and fungi. Emodin also generated DNA double strand breaks and stabilized the topo II-DNA cleavage complex (<xref rid="b27-bt-24-453" ref-type="bibr">Li <italic>et al</italic>., 2010</xref>).</p><p>Last group of topo II inhibitors are synthesized compounds designed from different scaffolds known to be biologically active or potent anti-cancer agents. Thiosemicarbazone (TSC) is one of the scaffolds, and their derivatives including TSC24 showed catalytic inhibition of topo II (<xref rid="b15-bt-24-453" ref-type="bibr">Huang <italic>et al</italic>., 2010</xref>). TSC24 directly bound to the ATPase domain which was confirmed by competitive inhibition assay, SPR and molecular docking studies. Baviskar and coworkers designed and synthesized bicyclic N-fused aminoimidazole which had similar structure to reported topo II inhibitors and marketed drugs such as zolpidem and zolimidine (<xref rid="b4-bt-24-453" ref-type="bibr">Baviskar <italic>et al</italic>., 2011</xref>). From the synthesized compounds, comp. 5 is a non-intercalating topo II catalytic inhibitor that bound to the ATP binding site. Compounds 14 and 14mod are xanthone derivatives that bound to the topo II ATPase domain, which was confirmed by ATPase competitive inhibition assay and molecular docking (<xref rid="b22-bt-24-453" ref-type="bibr">Jun <italic>et al</italic>., 2011</xref>; <xref rid="b36-bt-24-453" ref-type="bibr">Park <italic>et al</italic>., 2013</xref>). There were several topo II catalytic inhibitors containing quinone moiety that bound to the ATP binding site. Pyranonaphthoquinone, comp. 3a, was shown to be a topo II catalytic inhibitor and suggested to bind to the ATPase domain through docking (<xref rid="b21-bt-24-453" ref-type="bibr">Jimenez-Alonso <italic>et al</italic>., 2008</xref>). Naphthoquinone fused cyclic aminoalkyl-phosphonates and aminoalkyl-phosphonic monoester were synthesized and tested for their topo II activity (<xref rid="b48-bt-24-453" ref-type="bibr">Wang <italic>et al</italic>., 2008</xref>). Some of them including comp. 18 were catalytic topo II inhibitors and these compounds were docked into the ATP binding site of topo II (<xref rid="b29-bt-24-453" ref-type="bibr">Ma <italic>et al</italic>., 2011</xref>).</p></sec><sec><title>Hsp90 inhibitors that bind to the N-terminal ATPase domain</title><p>Geldanamycin (GDA) and radicicol (RDC), antibiotic isolated from natural product (<xref rid="b42-bt-24-453" ref-type="bibr">Roe <italic>et al</italic>., 1999</xref>) were the first discovered Hsp90 inhibitors that target the N-terminal ATPase domain. Due to poor solubility and hepatotoxicity of GDA and RDC, GDA and RDC derivatives were designed and synthesized to have good physical properties and stability with improved potency. 17-AAG is a GDA derivative that improved the toxicity and stability of GDA itself (<xref rid="b44-bt-24-453" ref-type="bibr">Schulte and Neckers, 1998</xref>). The co-crystal structure of 17-DMAG and Hsp90 N-terminal ATPase domain was solved (<xref rid="b20-bt-24-453" ref-type="bibr">Jez <italic>et al</italic>., 2003</xref>). GDA derivatives were also genetically engineered to produce GDA analogs, such as KOSN1559, showing better binding affinity than GDA (<xref rid="b37-bt-24-453" ref-type="bibr">Patel <italic>et al</italic>., 2004</xref>).</p><p>Another group of Hsp90 inhibitors are RDC analogs. KF25706, KF29163 and KF58333 were chemically synthesized and their biological activities were assessed (<xref rid="b46-bt-24-453" ref-type="bibr">Soga <italic>et al</italic>., 1999</xref>; <xref rid="b1-bt-24-453" ref-type="bibr">Agatsuma <italic>et al</italic>., 2002</xref>). Various RDC analogs were further synthesized such as aigialmycin D, c-RDC, pochonin A, pochonin D and O-(piperidinocarbonyl) methyloxime derivative of RDC.</p><p>The GDA and RDC analogs are rather big in size and their poor properties in solubility and toxicity led to designing and synthesizing purine analogs for inhibiting Hsp90 by binding to the ATP binding site. PU3 is one of them and it competed with GDA for Hsp90 binding and when treated in cancer cells, HER2 level decreased (<xref rid="b8-bt-24-453" ref-type="bibr">Chiosis <italic>et al</italic>., 2001</xref>). Other small Hsp90 inhibitors include pyrazole analogs such as CCT018159 and G3130. CCT018159 was searched from high-throughput screening compound collection of more than 56,000 compounds utilizing the ATPase activity assay (<xref rid="b43-bt-24-453" ref-type="bibr">Rowlands <italic>et al</italic>., 2004</xref>). The crystal structure of G3130 bound to the N-terminal ATP binding domain of Hsp90 was solved and the value of K<sub>d</sub> was 280 nM determined by SPR (<xref rid="b24-bt-24-453" ref-type="bibr">Kreusch <italic>et al</italic>., 2005</xref>). SNX0723 is one of the synthetic compound having a novel scaffold containing benzamide moiety which was discovered to bind to the ATPase domain of Hsp90 by screening a compound library (<xref rid="b40-bt-24-453" ref-type="bibr">Putcha <italic>et al</italic>., 2010</xref>). Resorcinol moiety was also identified to be an important scaffold for ATPase binding in Hsp90. AUY922, AT-13387 and CPUY201112 are the Hsp90 inhibitors that have resorcinol moiety which plays an important role in hydrogen bonding and hydrophobic interactions with the receptor (<xref rid="b9-bt-24-453" ref-type="bibr">Dutta Gupta <italic>et al</italic>., 2014</xref>). Hsp90 inhibitors targeting its N-terminal ATP binding site reviewed in the current study are listed in <xref rid="t3-bt-24-453" ref-type="table">Table 3</xref>.</p></sec><sec><title>Molecular docking studies</title><p>The similar molecular environment in the ATP binding sites of topo II and Hsp90 led us to assess whether reported inhibitors targeting either topo II or Hsp90 could function as a dual inhibitor. The listed topo II and Hsp90 inhibitors mentioned above were subjected for docking against both topo II and Hsp90. <xref rid="t4-bt-24-453" ref-type="table">Tables 4</xref> and <xref rid="t5-bt-24-453" ref-type="table">5</xref> list the docking results of topo II and Hsp90, respectively. Surflex-Dock gives total score, crash and polar values for each of conformers. Generally, the inhibitors targeting their own binding partner scored high total score. Interestingly, the best scoring inhibitor for topo II was PU3, which was reported as an Hsp90 inhibitor with purine ring. The inhibitors showing good docking score for Hsp90 did not perform well with topo II ATP binding site. This may be due to smaller mouth opening in ATP binding pocket of topo II than Hsp90 which was calculated from CASTp. The typical Hsp90 inhibitors are bulkier compared to topo II inhibitors, therefore it would be difficult for bulky Hsp90 inhibitors to enter into the topo II ATP binding pocket.</p><p>PU3, 8-Cl-ATP and compound 3t in the docking of topo II, all showed high docking score which are all purine analogs. Fascinatingly, PU3, an Hsp90 inhibitor, scored the highest when docked to topo II. PU3 had hydrogen bonding interactions with Asn91, Asn120, Ala167 and Thr215, where they are key residues that formed hydrogen bonds with ATP (<xref rid="f4-bt-24-453" ref-type="fig">Fig. 4A</xref>). Also, PU3 had hydrophobic interactions with the residues comprising the ATP binding pocket, namely, Asn91, Asp94, Arg98, Asn120, Ile125, Ile141, Phe142, Ser149, Asn150, Thr159, Gly161, Arg162, Gly164, Ala167, Lys168 and Thr215. Compound 3t also occupied the ATP binding site and interacted with residues Asn91, Ala92, Asn95, Asn120, Pro126, Ile141, Phe142, Ser149, Gly164, Tyr165, Gly166, Ala167, Lys168, Thr215 and Ile217 (<xref rid="f4-bt-24-453" ref-type="fig">Fig. 4B</xref>). However, 3t had only one hydrogen bond interaction with residue Asn91. AUY922 is an Hsp90 inhibitor with isoxazole moiety. There are two hydroxyl substituents from the phenyl ring and amide group that can form hydrogen bonds with residues Asn95, Asn120 and Ser149. Since AUY922 is rather big molecule compared to PU3, 3t, comp. 14 and 8-Cl-ATP, larger number of residues are involved in van der Waals interaction, namely, Ile88, Asn91, Ala92, Asn95, Arg98, Ile118, Asn120, Il2125, Pro126, Ile141, Phe142, Ser149, Asn150, Gly161, Gly164, Tyr165, Gly166, Ala167, Lys168, Thr215 and Ile217. Recently from AstraZeneca, compound with benzisoxazole scaffold, ETX0914, was discovered as a novel DNA gyrase inhibitor undergoing phase II clinical trial for the treatment of uncomplicated gonorrhea (<xref rid="b3-bt-24-453" ref-type="bibr">Basarab <italic>et al</italic>., 2015</xref>). There is no known topo II inhibitor reported with isoxazole scaffold to the best of our knowledge. Therefore our docking results suggest AUY922 may act as a topo II inhibitor with novel scaffold. Comp. 14 is a small compound with xanthone moiety which competed with ATP. Comp. 14 had hydrogen bond interactions with Asp94 and Thr215 and hydrophobic interactions with Asn51, Ser52, Ala55, Asp93, Ile96, Gly97, Met98, Asn106, Phe138, Val150, Thr184 and Val186.</p><p>In the case of docking topo II and Hsp90 inhibitors to Hsp90, the bulky Hsp90 inhibitors were high in rank as mentioned above. However, AUY922, a rather smaller isoxazole derivative compared to classical Hsp90 inhibitors such as GDM or RDC, scored highest. AUY922 also had hydrogen bond interactions with five residues in the ATP binding site of Hsp90, Asn51, Lys58, Asp93, Gly97 and Phe138. The residues involved in hydrophobic interactions are Asn51, Ala55, Lys59, Asp93, Ile96, Gly97, Met98, Asp102, Leu107, Gly135, Val136, Gly137, Phe138, Val150, Thr184 and Val186. PU3, a purine analog Hsp90 inhibitor showed good result in Hsp90 along with 3t, another purine analog topo II inhibitor.</p><p>Two purine derivatives of PU3 and 3t and two non-purine compounds of AUY922 and comp. 14 were selected for further comparison in depth since they ranked high in docking study of both topo II and Hsp90. The binding interactions of topo II and Hsp90 with compounds of PU3, 3t, AUY922 and 14 are shown in <xref rid="f4-bt-24-453" ref-type="fig">Fig. 4</xref>, <xref rid="f5-bt-24-453" ref-type="fig">5</xref>. The hydrogen bonding residues are labeled and the bonds are displayed as light blue dashed lines. The selected common four compounds and high scoring compounds 8-Cl-ATP and KOSN1599 for topo II and Hsp90, respectively, were analyzed in detail. <xref rid="t6-bt-24-453" ref-type="table">Table 6</xref> summarizes the residues involved in hydrophobic and hydrogen bond interactions.</p></sec><sec><title>Pharmacophore model analysis</title><p>Compounds PU3, 3t, AUY922 and comp. 14 were further evaluated for their dual targeting features by generating pharmacophore models. The pharmacophore model was generated using Genetic Algorithm Similarity Program (GASP) module implemented in Sybyl X-2.1.1. From the four compounds, four models were generated by GASP. The fitness score for each model ranged from 2589.82 to 2689.23 and model 2 was chosen as the best model (<xref rid="t7-bt-24-453" ref-type="table">Table 7</xref>). Model 2 consists of two hydrophobic regions (HY, cyan), one acceptor atom (AA, green) and one donor site (DS, green) as shown in <xref rid="f6-bt-24-453" ref-type="fig">Fig. 6</xref> with PU3 as the template. The two hydrophobic regions are about 5 &#x000c5; apart and the hydrophobic region 1 and the acceptor atom is 2.5 &#x000c5; apart. The pharmacophore model suggested here can be used as a template to further optimize the design of the dual inhibitor of topo II and Hsp90.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSIONS</title><p>In this study, the inhibitors reported to target each ATPase domain of human topo II and Hsp90 were investigated. The structures of ATPase domains of topo II and Hsp90 were compared to evaluate how similar the environment of the receptor sites were. The topo II and Hsp90 inhibitors known to target the ATP binding site were searched and the possibility to function as a dual inhibitor was investigated <italic>in silico</italic>. All the inhibitors searched were docked to both topo II and Hsp90. Through the analysis of docking results, four candidate compounds were selected as possible dual inhibitors. These compounds were used as a template to generate pharmacophore model. This suggested pharmacophore model will be useful in developing dual inhibitor of topo II and Hsp90 by constructing 3D query for virtual screening using publically available database such as ZINC (<ext-link ext-link-type="uri" xlink:href="http://zinc.docking.org/">http://zinc.docking.org/</ext-link>).</p></sec></body><back><ack><p>This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (NRF-2013R1A1A2060408), the Korean Health Technology R&#x00026;D Project funded by Ministry of Health &#x00026; Welfare, Republic of Korea (HI14C2469), and by the grant of the Bio &#x00026; Medical Technology Development Program (NRF-2014M3A9A9073 908) of the National Research Foundation of Korea (NRF), funded by the Korean government (Ministry of Science, ICT &#x00026; Future Planning).</p></ack><ref-list><title>REFERENCES</title><ref id="b1-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agatsuma</surname><given-names>T</given-names></name><name><surname>Ogawa</surname><given-names>H</given-names></name><name><surname>Akasaka</surname><given-names>K</given-names></name><name><surname>Asai</surname><given-names>A</given-names></name><name><surname>Yamashita</surname><given-names>Y</given-names></name><name><surname>Mizukami</surname><given-names>T</given-names></name><name><surname>Akinaga</surname><given-names>S</given-names></name><name><surname>Saitoh</surname><given-names>Y</given-names></name></person-group><year>2002</year><article-title>Halohydrin and oxime derivatives of radicicol: Synthesis and antitumor activities</article-title><source>Bioorg Med Chem</source><volume>10</volume><fpage>3445</fpage><lpage>3454</lpage><pub-id pub-id-type="doi">10.1016/S0968-0896(02)00260-2</pub-id><?supplied-pmid 12213458?><pub-id pub-id-type="pmid">12213458</pub-id></element-citation></ref><ref id="b2-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barker</surname><given-names>CR</given-names></name><name><surname>Hamlett</surname><given-names>J</given-names></name><name><surname>Pennington</surname><given-names>SR</given-names></name><name><surname>Burrows</surname><given-names>F</given-names></name><name><surname>Lundgren</surname><given-names>K</given-names></name><name><surname>Lough</surname><given-names>R</given-names></name><name><surname>Watson</surname><given-names>AJ</given-names></name><name><surname>Jenkins</surname><given-names>JR</given-names></name></person-group><year>2006</year><article-title>The topoisomerase II-Hsp90 complex: A new chemotherapeutic target?</article-title><source>Int. J. Cancer</source><volume>118</volume><fpage>2685</fpage><lpage>2693</lpage><pub-id pub-id-type="doi">10.1002/ijc.21717</pub-id><pub-id pub-id-type="pmid">16385570</pub-id></element-citation></ref><ref id="b3-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basarab</surname><given-names>GS</given-names></name><name><surname>Kern</surname><given-names>GH</given-names></name><name><surname>McNulty</surname><given-names>J</given-names></name><name><surname>Mueller</surname><given-names>JP</given-names></name><name><surname>Lawrence</surname><given-names>K</given-names></name><name><surname>Vishwanathan</surname><given-names>K</given-names></name><name><surname>Alm</surname><given-names>RA</given-names></name><name><surname>Barvian</surname><given-names>K</given-names></name><name><surname>Doig</surname><given-names>P</given-names></name><name><surname>Galullo</surname><given-names>V</given-names></name><name><surname>Gardner</surname><given-names>H</given-names></name><name><surname>Gowravaram</surname><given-names>M</given-names></name><name><surname>Huband</surname><given-names>M</given-names></name><name><surname>Kimzey</surname><given-names>A</given-names></name><name><surname>Morningstar</surname><given-names>M</given-names></name><name><surname>Kutschke</surname><given-names>A</given-names></name><name><surname>Lahiri</surname><given-names>SD</given-names></name><name><surname>Perros</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Schuck</surname><given-names>VJ</given-names></name><name><surname>Tommasi</surname><given-names>R</given-names></name><name><surname>Walkup</surname><given-names>G</given-names></name><name><surname>Newman</surname><given-names>JV</given-names></name></person-group><year>2015</year><article-title>Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases</article-title><source>Sci Rep</source><volume>5</volume><fpage>11827</fpage><pub-id pub-id-type="doi">10.1038/srep11827</pub-id><!--<pub-id pub-id-type="pmcid">4501059</pub-id>--><?supplied-pmid 26168713?><pub-id pub-id-type="pmid">26168713</pub-id></element-citation></ref><ref id="b4-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baviskar</surname><given-names>AT</given-names></name><name><surname>Madaan</surname><given-names>C</given-names></name><name><surname>Preet</surname><given-names>R</given-names></name><name><surname>Mohapatra</surname><given-names>P</given-names></name><name><surname>Jain</surname><given-names>V</given-names></name><name><surname>Agarwal</surname><given-names>A</given-names></name><name><surname>Guchhait</surname><given-names>SK</given-names></name><name><surname>Kundu</surname><given-names>CN</given-names></name><name><surname>Banerjee</surname><given-names>UC</given-names></name><name><surname>Bharatam</surname><given-names>PV</given-names></name></person-group><year>2011</year><article-title>N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase II&#x003b1;and induce apoptosis in G1/S phase</article-title><source>J Med Chem</source><volume>54</volume><fpage>5013</fpage><lpage>5030</lpage><pub-id pub-id-type="doi">10.1021/jm200235u</pub-id><?supplied-pmid 21644529?><pub-id pub-id-type="pmid">21644529</pub-id></element-citation></ref><ref id="b5-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brough</surname><given-names>PA</given-names></name><name><surname>Aherne</surname><given-names>W</given-names></name><name><surname>Barril</surname><given-names>X</given-names></name><name><surname>Borgognoni</surname><given-names>J</given-names></name><name><surname>Boxall</surname><given-names>K</given-names></name><name><surname>Cansfield</surname><given-names>JE</given-names></name><name><surname>Cheung</surname><given-names>KM</given-names></name><name><surname>Collins</surname><given-names>I</given-names></name><name><surname>Davies</surname><given-names>NG</given-names></name><name><surname>Drysdale</surname><given-names>MJ</given-names></name><name><surname>Dymock</surname><given-names>B</given-names></name><name><surname>Eccles</surname><given-names>SA</given-names></name><name><surname>Finch</surname><given-names>H</given-names></name><name><surname>Fink</surname><given-names>A</given-names></name><name><surname>Hayes</surname><given-names>A</given-names></name><name><surname>Howes</surname><given-names>R</given-names></name><name><surname>Hubbard</surname><given-names>RE</given-names></name><name><surname>James</surname><given-names>K</given-names></name><name><surname>Jordan</surname><given-names>AM</given-names></name><name><surname>Lockie</surname><given-names>A</given-names></name><name><surname>Martins</surname><given-names>V</given-names></name><name><surname>Massey</surname><given-names>A</given-names></name><name><surname>Matthews</surname><given-names>TP</given-names></name><name><surname>McDonald</surname><given-names>E</given-names></name><name><surname>Northfield</surname><given-names>CJ</given-names></name><name><surname>Pearl</surname><given-names>LH</given-names></name><name><surname>Prodromou</surname><given-names>C</given-names></name><name><surname>Ray</surname><given-names>S</given-names></name><name><surname>Raynaud</surname><given-names>FI</given-names></name><name><surname>Roughley</surname><given-names>SD</given-names></name><name><surname>Sharp</surname><given-names>SY</given-names></name><name><surname>Surgenor</surname><given-names>A</given-names></name><name><surname>Walmsley</surname><given-names>DL</given-names></name><name><surname>Webb</surname><given-names>P</given-names></name><name><surname>Wood</surname><given-names>M</given-names></name><name><surname>Workman</surname><given-names>P</given-names></name><name><surname>Wright</surname><given-names>L</given-names></name></person-group><year>2008</year><article-title>4,5-diarylisoxazole Hsp90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer</article-title><source>J Med Chem</source><volume>51</volume><fpage>196</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1021/jm701018h</pub-id><pub-id pub-id-type="pmid">18020435</pub-id></element-citation></ref><ref id="b6-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chene</surname><given-names>P</given-names></name></person-group><year>2002</year><article-title>ATPases as drug targets: Learning from their structure</article-title><source>Nat Rev Drug Discov</source><volume>1</volume><fpage>665</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1038/nrd894</pub-id><?supplied-pmid 12209147?><pub-id pub-id-type="pmid">12209147</pub-id></element-citation></ref><ref id="b7-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chene</surname><given-names>P</given-names></name><name><surname>Rudloff</surname><given-names>J</given-names></name><name><surname>Schoepfer</surname><given-names>J</given-names></name><name><surname>Furet</surname><given-names>P</given-names></name><name><surname>Meier</surname><given-names>P</given-names></name><name><surname>Qian</surname><given-names>Z</given-names></name><name><surname>Schlaeppi</surname><given-names>JM</given-names></name><name><surname>Schmitz</surname><given-names>R</given-names></name><name><surname>Radimerski</surname><given-names>T</given-names></name></person-group><year>2009</year><article-title>Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue</article-title><source>BMC Chem Biol</source><volume>9</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1186/1472-6769-9-1</pub-id><!--<pub-id pub-id-type="pmcid">2628638</pub-id>--><?supplied-pmid 19128485?><pub-id pub-id-type="pmid">19128485</pub-id></element-citation></ref><ref id="b8-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiosis</surname><given-names>G</given-names></name><name><surname>Timaul</surname><given-names>MN</given-names></name><name><surname>Lucas</surname><given-names>B</given-names></name><name><surname>Munster</surname><given-names>PN</given-names></name><name><surname>Zheng</surname><given-names>FF</given-names></name><name><surname>Sepp-Lorenzino</surname><given-names>L</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name></person-group><year>2001</year><article-title>A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells</article-title><source>Chem Biol</source><volume>8</volume><fpage>289</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1016/S1074-5521(01)00015-1</pub-id><?supplied-pmid 11306353?><pub-id pub-id-type="pmid">11306353</pub-id></element-citation></ref><ref id="b9-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dutta Gupta</surname><given-names>S</given-names></name><name><surname>Snigdha</surname><given-names>D</given-names></name><name><surname>Mazaira</surname><given-names>GI</given-names></name><name><surname>Galigniana</surname><given-names>MD</given-names></name><name><surname>Subrahmanyam</surname><given-names>CV</given-names></name><name><surname>Gowrishankar</surname><given-names>NL</given-names></name><name><surname>Raghavendra</surname><given-names>NM</given-names></name></person-group><year>2014</year><article-title>Molecular docking study, synthesis and biological evaluation of schiff bases as Hsp90 inhibitors</article-title><source>Biomed Pharmacother</source><volume>68</volume><fpage>369</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2014.01.003</pub-id><?supplied-pmid 24486109?><pub-id pub-id-type="pmid">24486109</pub-id></element-citation></ref><ref id="b10-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dutta</surname><given-names>R</given-names></name><name><surname>Inouye</surname><given-names>M</given-names></name></person-group><year>2000</year><article-title>GHKL, an emergent ATPase/kinase superfamily</article-title><source>Trends Biochem Sci</source><volume>25</volume><fpage>24</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/S0968-0004(99)01503-0</pub-id><?supplied-pmid 10637609?><pub-id pub-id-type="pmid">10637609</pub-id></element-citation></ref><ref id="b11-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furet</surname><given-names>P</given-names></name><name><surname>Schoepfer</surname><given-names>J</given-names></name><name><surname>Radimerski</surname><given-names>T</given-names></name><name><surname>Ch&#x000e8;ne</surname><given-names>P</given-names></name></person-group><year>2009</year><article-title>Discovery of a new class of catalytic topoisomerase II inhibitors targeting the atp-binding site by structure based design. Part I</article-title><source>Bioorg Med Chem Lett</source><volume>19</volume><fpage>4014</fpage><lpage>4017</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2009.06.034</pub-id><?supplied-pmid 19560355?><pub-id pub-id-type="pmid">19560355</pub-id></element-citation></ref><ref id="b12-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gui</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>DK</given-names></name><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>QM</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Feng</surname><given-names>JM</given-names></name><name><surname>Liu</surname><given-names>CH</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>YX</given-names></name><name><surname>Geng</surname><given-names>M</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name></person-group><year>2011</year><article-title>D11, a novel glycosylated diphyllin derivative, exhibits potent anticancer activity by targeting topoisomerase II&#x003b1;</article-title><source>Invest. New Drugs</source><volume>29</volume><fpage>800</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1007/s10637-010-9425-3</pub-id><pub-id pub-id-type="pmid">20336347</pub-id></element-citation></ref><ref id="b13-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>TA</given-names></name></person-group><year>1999</year><article-title>BioEdit: A user-friendly biological sequence alignment editor and analysis program for windows 95/98/nt</article-title><source>Nucl Acids Symp Ser</source><volume>41</volume><fpage>95</fpage><lpage>98</lpage></element-citation></ref><ref id="b14-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>CX</given-names></name><name><surname>Zuo</surname><given-names>ZL</given-names></name><name><surname>Xiong</surname><given-names>B</given-names></name><name><surname>Ma</surname><given-names>JG</given-names></name><name><surname>Geng</surname><given-names>MY</given-names></name><name><surname>Lin</surname><given-names>LP</given-names></name><name><surname>Jiang</surname><given-names>HL</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name></person-group><year>2006</year><article-title>Salvicine functions as novel topoisomerase II poison by binding to ATP pocket</article-title><source>Mol Pharmacol</source><volume>70</volume><fpage>1593</fpage><lpage>1601</lpage><pub-id pub-id-type="doi">10.1124/mol.106.027714</pub-id><?supplied-pmid 16914642?><pub-id pub-id-type="pmid">16914642</pub-id></element-citation></ref><ref id="b15-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Ku</surname><given-names>X</given-names></name><name><surname>Meng</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name></person-group><year>2010</year><article-title>A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase iialpha catalytic activity</article-title><source>J Med Chem</source><volume>53</volume><fpage>3048</fpage><lpage>3064</lpage><pub-id pub-id-type="doi">10.1021/jm9014394</pub-id><?supplied-pmid 20353152?><pub-id pub-id-type="pmid">20353152</pub-id></element-citation></ref><ref id="b16-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikuina</surname><given-names>Y</given-names></name><name><surname>Amishiro</surname><given-names>N</given-names></name><name><surname>Miyata</surname><given-names>M</given-names></name><name><surname>Narumi</surname><given-names>H</given-names></name><name><surname>Ogawa</surname><given-names>H</given-names></name><name><surname>Akiyama</surname><given-names>T</given-names></name><name><surname>Shiotsu</surname><given-names>Y</given-names></name><name><surname>Akinaga</surname><given-names>S</given-names></name><name><surname>Murakata</surname><given-names>C</given-names></name></person-group><year>2003</year><article-title>Synthesis and antitumor activity of novel o-carbamoylmethyloxime derivatives of radicicol</article-title><source>J Med Chem</source><volume>46</volume><fpage>2534</fpage><lpage>2541</lpage><pub-id pub-id-type="doi">10.1021/jm030110r</pub-id><?supplied-pmid 12773056?><pub-id pub-id-type="pmid">12773056</pub-id></element-citation></ref><ref id="b17-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>AN</given-names></name></person-group><year>2003</year><article-title>Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine</article-title><source>J Med Chem</source><volume>46</volume><fpage>499</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1021/jm020406h</pub-id><?supplied-pmid 12570372?><pub-id pub-id-type="pmid">12570372</pub-id></element-citation></ref><ref id="b18-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>LH</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Shoemaker</surname><given-names>R</given-names></name><name><surname>Grauslund</surname><given-names>M</given-names></name><name><surname>Sehested</surname><given-names>M</given-names></name><name><surname>Hasinoff</surname><given-names>BB</given-names></name></person-group><year>2006</year><article-title>A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs</article-title><source>Mol Pharmacol</source><volume>70</volume><fpage>1503</fpage><lpage>1513</lpage><pub-id pub-id-type="doi">10.1124/mol.106.026856</pub-id><?supplied-pmid 16880287?><pub-id pub-id-type="pmid">16880287</pub-id></element-citation></ref><ref id="b19-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>LH</given-names></name><name><surname>Thougaard</surname><given-names>AV</given-names></name><name><surname>Grauslund</surname><given-names>M</given-names></name><name><surname>Sokilde</surname><given-names>B</given-names></name><name><surname>Carstensen</surname><given-names>EV</given-names></name><name><surname>Dvinge</surname><given-names>HK</given-names></name><name><surname>Scudiero</surname><given-names>DA</given-names></name><name><surname>Jensen</surname><given-names>PB</given-names></name><name><surname>Shoemaker</surname><given-names>RH</given-names></name><name><surname>Sehested</surname><given-names>M</given-names></name></person-group><year>2005</year><article-title>Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors</article-title><source>Cancer Res</source><volume>65</volume><fpage>7470</fpage><lpage>7477</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-0707</pub-id><?supplied-pmid 16103101?><pub-id pub-id-type="pmid">16103101</pub-id></element-citation></ref><ref id="b20-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jez</surname><given-names>JM</given-names></name><name><surname>Chen</surname><given-names>JC</given-names></name><name><surname>Rastelli</surname><given-names>G</given-names></name><name><surname>Stroud</surname><given-names>RM</given-names></name><name><surname>Santi</surname><given-names>DV</given-names></name></person-group><year>2003</year><article-title>Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90</article-title><source>Chem Biol</source><volume>10</volume><fpage>361</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1016/S1074-5521(03)00075-9</pub-id><?supplied-pmid 12725864?><pub-id pub-id-type="pmid">12725864</pub-id></element-citation></ref><ref id="b21-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jimenez-Alonso</surname><given-names>S</given-names></name><name><surname>Orellana</surname><given-names>HC</given-names></name><name><surname>Estevez-Braun</surname><given-names>A</given-names></name><name><surname>Ravelo</surname><given-names>AG</given-names></name><name><surname>Perez-Sacau</surname><given-names>E</given-names></name><name><surname>Machin</surname><given-names>F</given-names></name></person-group><year>2008</year><article-title>Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors</article-title><source>J Med Chem</source><volume>51</volume><fpage>6761</fpage><lpage>6772</lpage><pub-id pub-id-type="doi">10.1021/jm800499x</pub-id><?supplied-pmid 18816045?><pub-id pub-id-type="pmid">18816045</pub-id></element-citation></ref><ref id="b22-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jun</surname><given-names>KY</given-names></name><name><surname>Lee</surname><given-names>EY</given-names></name><name><surname>Jung</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>OH</given-names></name><name><surname>Lee</surname><given-names>ES</given-names></name><name><surname>Park Choo</surname><given-names>HY</given-names></name><name><surname>Na</surname><given-names>Y</given-names></name><name><surname>Kwon</surname><given-names>Y</given-names></name></person-group><year>2011</year><article-title>Synthesis, biological evaluation, and molecular docking study of 3-(3&#x02032;-heteroatom substituted-2&#x02032;-hydroxy-1&#x02032;-propyloxy) xanthone analogues as novel topoisomerase II&#x003b1; catalytic inhibitor</article-title><source>Eur J Med Chem</source><volume>46</volume><fpage>1964</fpage><lpage>1971</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2011.01.011</pub-id><?supplied-pmid 21419530?><pub-id pub-id-type="pmid">21419530</pub-id></element-citation></ref><ref id="b23-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>K</given-names></name><name><surname>Nho</surname><given-names>CW</given-names></name><name><surname>Kim</surname><given-names>ND</given-names></name><name><surname>Song</surname><given-names>DG</given-names></name><name><surname>Park</surname><given-names>YG</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Pan</surname><given-names>CH</given-names></name><name><surname>Shin</surname><given-names>D</given-names></name><name><surname>Oh</surname><given-names>SH</given-names></name><name><surname>Oh</surname><given-names>HS</given-names></name></person-group><year>2014</year><article-title>Daurinol, a catalytic inhibitor of topoisomerase II&#x003b1;, suppresses SNU-840 ovarian cancer cell proliferation through cell cycle arrest in S phase</article-title><source>Int J Oncol</source><volume>45</volume><fpage>558</fpage><lpage>566</lpage><?supplied-pmid 24841075?><pub-id pub-id-type="pmid">24841075</pub-id></element-citation></ref><ref id="b24-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreusch</surname><given-names>A</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Brinker</surname><given-names>A</given-names></name><name><surname>Zhou</surname><given-names>V</given-names></name><name><surname>Choi</surname><given-names>HS</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Lesley</surname><given-names>SA</given-names></name><name><surname>Caldwell</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>XJ</given-names></name></person-group><year>2005</year><article-title>Crystal structures of human HSP90alpha-complexed with dihydroxyphenylpyrazoles</article-title><source>Bioorg Med Chem Lett</source><volume>15</volume><fpage>1475</fpage><lpage>1478</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2004.12.087</pub-id><?supplied-pmid 15713410?><pub-id pub-id-type="pmid">15713410</pub-id></element-citation></ref><ref id="b25-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kung</surname><given-names>PP</given-names></name><name><surname>Funk</surname><given-names>L</given-names></name><name><surname>Meng</surname><given-names>J</given-names></name><name><surname>Collins</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>JZ</given-names></name><name><surname>Johnson</surname><given-names>MC</given-names></name><name><surname>Ekker</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Mehta</surname><given-names>P</given-names></name><name><surname>Yin</surname><given-names>MJ</given-names></name><name><surname>Rodgers</surname><given-names>C</given-names></name><name><surname>Davies</surname><given-names>JF</given-names><suffix>2nd</suffix></name><name><surname>Bayman</surname><given-names>E</given-names></name><name><surname>Smeal</surname><given-names>T</given-names></name><name><surname>Maegley</surname><given-names>KA</given-names></name><name><surname>Gehring</surname><given-names>MR</given-names></name></person-group><year>2008</year><article-title>Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone</article-title><source>Bioorg Med Chem Lett</source><volume>18</volume><fpage>6273</fpage><lpage>6278</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2008.09.081</pub-id><?supplied-pmid 18929486?><pub-id pub-id-type="pmid">18929486</pub-id></element-citation></ref><ref id="b26-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>PH</given-names></name><name><surname>Zeng</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>SB</given-names></name><name><surname>Yao</surname><given-names>PF</given-names></name><name><surname>Mai</surname><given-names>YW</given-names></name><name><surname>Tan</surname><given-names>JH</given-names></name><name><surname>Ou</surname><given-names>TM</given-names></name><name><surname>Huang</surname><given-names>SL</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Gu</surname><given-names>LQ</given-names></name><name><surname>Huang</surname><given-names>ZS</given-names></name></person-group><year>2016</year><article-title>Synthesis and mechanism studies of 1,3-benzoazolyl substituted pyrrolo[2,3-b]pyrazine derivatives as nonintercalative topoisomerase II catalytic inhibitors</article-title><source>J Med Chem</source><volume>59</volume><fpage>238</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01284</pub-id><pub-id pub-id-type="pmid">26649766</pub-id></element-citation></ref><ref id="b27-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Luan</surname><given-names>Y</given-names></name><name><surname>Qi</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Gong</surname><given-names>L</given-names></name><name><surname>Xue</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Xing</surname><given-names>G</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Ren</surname><given-names>J</given-names></name></person-group><year>2010</year><article-title>Emodin triggers DNA double-strand breaks by stabilizing topoisomerase II-DNA cleavage complexes and by inhibiting atp hydrolysis of topoisomerase II</article-title><source>Toxicol Sci</source><volume>118</volume><fpage>435</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1093/toxsci/kfq282</pub-id><?supplied-pmid 20855424?><pub-id pub-id-type="pmid">20855424</pub-id></element-citation></ref><ref id="b28-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Edelsbrunner</surname><given-names>H</given-names></name><name><surname>Woodward</surname><given-names>C</given-names></name></person-group><year>1998</year><article-title>Anatomy of protein pockets and cavities: Measurement of binding site geometry and implications for ligand design</article-title><source>Protein Sci</source><volume>7</volume><fpage>1884</fpage><lpage>1897</lpage><pub-id pub-id-type="doi">10.1002/pro.5560070905</pub-id><!--<pub-id pub-id-type="pmcid">2144175</pub-id>--><?supplied-pmid 9761470?><pub-id pub-id-type="pmid">9761470</pub-id></element-citation></ref><ref id="b29-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>JG</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>ZM</given-names></name></person-group><year>2011</year><article-title>Integrating molecular docking, DFT and CoMFA/CoMSIA approaches for a series of naphthoquinone fused cyclic &#x003b1;-aminophosphonates that act as novel topoisomerase II inhibitors</article-title><source>J Mol Model</source><volume>17</volume><fpage>1899</fpage><lpage>1909</lpage><pub-id pub-id-type="doi">10.1007/s00894-010-0898-y</pub-id><pub-id pub-id-type="pmid">21107989</pub-id></element-citation></ref><ref id="b30-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moulin</surname><given-names>E</given-names></name><name><surname>Barluenga</surname><given-names>S</given-names></name><name><surname>Winssinger</surname><given-names>N</given-names></name></person-group><year>2005a</year><article-title>Concise synthesis of pochonin A, an HSP90 inhibitor</article-title><source>Org Lett</source><volume>7</volume><fpage>5637</fpage><lpage>5639</lpage><pub-id pub-id-type="doi">10.1021/ol052263+</pub-id><pub-id pub-id-type="pmid">16321010</pub-id></element-citation></ref><ref id="b31-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moulin</surname><given-names>E</given-names></name><name><surname>Zoete</surname><given-names>V</given-names></name><name><surname>Barluenga</surname><given-names>S</given-names></name><name><surname>Karplus</surname><given-names>M</given-names></name><name><surname>Winssinger</surname><given-names>N</given-names></name></person-group><year>2005b</year><article-title>Design, synthesis, and biological evaluation of HSP90 inhibitors based on conformational analysis of radicicol and its analogues</article-title><source>J Am Chem Soc</source><volume>127</volume><fpage>6999</fpage><lpage>7004</lpage><pub-id pub-id-type="doi">10.1021/ja043101w</pub-id><pub-id pub-id-type="pmid">15884943</pub-id></element-citation></ref><ref id="b32-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>CW</given-names></name><name><surname>Carr</surname><given-names>MG</given-names></name><name><surname>Callaghan</surname><given-names>O</given-names></name><name><surname>Chessari</surname><given-names>G</given-names></name><name><surname>Congreve</surname><given-names>M</given-names></name><name><surname>Cowan</surname><given-names>S</given-names></name><name><surname>Coyle</surname><given-names>JE</given-names></name><name><surname>Downham</surname><given-names>R</given-names></name><name><surname>Figueroa</surname><given-names>E</given-names></name><name><surname>Frederickson</surname><given-names>M</given-names></name><name><surname>Graham</surname><given-names>B</given-names></name><name><surname>McMenamin</surname><given-names>R</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>MA</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Phillips</surname><given-names>TR</given-names></name><name><surname>Williams</surname><given-names>G</given-names></name><name><surname>Woodhead</surname><given-names>AJ</given-names></name><name><surname>Woolford</surname><given-names>AJ</given-names></name></person-group><year>2010</year><article-title>Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency</article-title><source>J Med Chem</source><volume>53</volume><fpage>5942</fpage><lpage>5955</lpage><pub-id pub-id-type="doi">10.1021/jm100059d</pub-id><?supplied-pmid 20718493?><pub-id pub-id-type="pmid">20718493</pub-id></element-citation></ref><ref id="b33-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neckers</surname><given-names>L</given-names></name></person-group><year>2002</year><article-title>Hsp90 inhibitors as novel cancer chemotherapeutic agents</article-title><source>Trends Mol Med</source><volume>8</volume><fpage>S55</fpage><lpage>S61</lpage><pub-id pub-id-type="doi">10.1016/S1471-4914(02)02316-X</pub-id><?supplied-pmid 11927289?><pub-id pub-id-type="pmid">11927289</pub-id></element-citation></ref><ref id="b34-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nitiss</surname><given-names>JL</given-names></name></person-group><year>2009a</year><article-title>Targeting DNA topoisomerase II in cancer chemotherapy</article-title><source>Nat. Rev. Cancer</source><volume>9</volume><fpage>338</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1038/nrc2607</pub-id><pub-id pub-id-type="pmid">19377506</pub-id></element-citation></ref><ref id="b35-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nitiss</surname><given-names>JL</given-names></name></person-group><year>2009b</year><article-title>DNA topoisomerase II and its growing repertoire of biological functions</article-title><source>Nat. Rev. Cancer</source><volume>9</volume><fpage>327</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1038/nrc2608</pub-id><pub-id pub-id-type="pmid">19377505</pub-id></element-citation></ref><ref id="b36-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>SE</given-names></name><name><surname>Chang</surname><given-names>IH</given-names></name><name><surname>Jun</surname><given-names>KY</given-names></name><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>ES</given-names></name><name><surname>Na</surname><given-names>Y</given-names></name><name><surname>Kwon</surname><given-names>Y</given-names></name></person-group><year>2013</year><article-title>3-(3-butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase II&#x003b1; catalytic inhibitor with low DNA damage</article-title><source>Eur J Med Chem</source><volume>69</volume><fpage>139</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2013.07.048</pub-id><?supplied-pmid 24013413?><pub-id pub-id-type="pmid">24013413</pub-id></element-citation></ref><ref id="b37-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>K</given-names></name><name><surname>Piagentini</surname><given-names>M</given-names></name><name><surname>Rascher</surname><given-names>A</given-names></name><name><surname>Tian</surname><given-names>ZQ</given-names></name><name><surname>Buchanan</surname><given-names>GO</given-names></name><name><surname>Regentin</surname><given-names>R</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Hutchinson</surname><given-names>CR</given-names></name><name><surname>McDaniel</surname><given-names>R</given-names></name></person-group><year>2004</year><article-title>Engineered biosynthesis of geldanamycin analogs for Hsp90 inhibition</article-title><source>Chem Biol</source><volume>11</volume><fpage>1625</fpage><lpage>1633</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2004.09.012</pub-id><?supplied-pmid 15610846?><pub-id pub-id-type="pmid">15610846</pub-id></element-citation></ref><ref id="b38-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrelli</surname><given-names>A</given-names></name><name><surname>Giordano</surname><given-names>S</given-names></name></person-group><year>2008</year><article-title>From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage</article-title><source>Curr Med Chem</source><volume>15</volume><fpage>422</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.2174/092986708783503212</pub-id><?supplied-pmid 18288997?><pub-id pub-id-type="pmid">18288997</pub-id></element-citation></ref><ref id="b39-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pogorelcnik</surname><given-names>B</given-names></name><name><surname>Perdih</surname><given-names>A</given-names></name><name><surname>Solmajer</surname><given-names>T</given-names></name></person-group><year>2013</year><article-title>Recent advances in the development of catalytic inhibitors of human DNA topoisomerase II&#x003b1; as novel anticancer agents</article-title><source>Curr Med Chem</source><volume>20</volume><fpage>694</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.2174/092986713804999402</pub-id><pub-id pub-id-type="pmid">23210851</pub-id></element-citation></ref><ref id="b40-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Putcha</surname><given-names>P</given-names></name><name><surname>Danzer</surname><given-names>KM</given-names></name><name><surname>Kranich</surname><given-names>LR</given-names></name><name><surname>Scott</surname><given-names>A</given-names></name><name><surname>Silinski</surname><given-names>M</given-names></name><name><surname>Mabbett</surname><given-names>S</given-names></name><name><surname>Hicks</surname><given-names>CD</given-names></name><name><surname>Veal</surname><given-names>JM</given-names></name><name><surname>Steed</surname><given-names>PM</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>McLean</surname><given-names>PJ</given-names></name></person-group><year>2010</year><article-title>Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity</article-title><source>J Pharmacol Exp Ther</source><volume>332</volume><fpage>849</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1124/jpet.109.158436</pub-id><!--<pub-id pub-id-type="pmcid">2835433</pub-id>--><pub-id pub-id-type="pmid">19934398</pub-id></element-citation></ref><ref id="b41-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>Y</given-names></name><name><surname>Meng</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Duan</surname><given-names>W</given-names></name><name><surname>Zuo</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name></person-group><year>2007</year><article-title>Gambogic acid inhibits the catalytic activity of human topoisomerase II&#x003b1; by binding to its ATPase domain</article-title><source>Mol Cancer Ther</source><volume>6</volume><fpage>2429</fpage><lpage>2440</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-07-0147</pub-id><?supplied-pmid 17876042?><pub-id pub-id-type="pmid">17876042</pub-id></element-citation></ref><ref id="b42-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roe</surname><given-names>SM</given-names></name><name><surname>Prodromou</surname><given-names>C</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>R</given-names></name><name><surname>Ladbury</surname><given-names>JE</given-names></name><name><surname>Piper</surname><given-names>PW</given-names></name><name><surname>Pearl</surname><given-names>LH</given-names></name></person-group><year>1999</year><article-title>Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin</article-title><source>J Med Chem</source><volume>42</volume><fpage>260</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1021/jm980403y</pub-id><?supplied-pmid 9925731?><pub-id pub-id-type="pmid">9925731</pub-id></element-citation></ref><ref id="b43-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowlands</surname><given-names>MG</given-names></name><name><surname>Newbatt</surname><given-names>YM</given-names></name><name><surname>Prodromou</surname><given-names>C</given-names></name><name><surname>Pearl</surname><given-names>LH</given-names></name><name><surname>Workman</surname><given-names>P</given-names></name><name><surname>Aherne</surname><given-names>W</given-names></name></person-group><year>2004</year><article-title>High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity</article-title><source>Anal Biochem</source><volume>327</volume><fpage>176</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2003.10.038</pub-id><?supplied-pmid 15051534?><pub-id pub-id-type="pmid">15051534</pub-id></element-citation></ref><ref id="b44-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulte</surname><given-names>TW</given-names></name><name><surname>Neckers</surname><given-names>LM</given-names></name></person-group><year>1998</year><article-title>The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin</article-title><source>Cancer Chemother Pharmacol</source><volume>42</volume><fpage>273</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1007/s002800050817</pub-id><?supplied-pmid 9744771?><pub-id pub-id-type="pmid">9744771</pub-id></element-citation></ref><ref id="b45-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sidera</surname><given-names>K</given-names></name><name><surname>Patsavoudi</surname><given-names>E</given-names></name></person-group><year>2014</year><article-title>HSP90 inhibitors: current development and potential in cancer therapy</article-title><source>Recent Pat Anticancer Drug Discov</source><volume>9</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.2174/15748928113089990031</pub-id><pub-id pub-id-type="pmid">23312026</pub-id></element-citation></ref><ref id="b46-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soga</surname><given-names>S</given-names></name><name><surname>Neckers</surname><given-names>LM</given-names></name><name><surname>Schulte</surname><given-names>TW</given-names></name><name><surname>Shiotsu</surname><given-names>Y</given-names></name><name><surname>Akasaka</surname><given-names>K</given-names></name><name><surname>Narumi</surname><given-names>H</given-names></name><name><surname>Agatsuma</surname><given-names>T</given-names></name><name><surname>Ikuina</surname><given-names>Y</given-names></name><name><surname>Murakata</surname><given-names>C</given-names></name><name><surname>Tamaoki</surname><given-names>T</given-names></name><name><surname>Akinaga</surname><given-names>S</given-names></name></person-group><year>1999</year><article-title>KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules</article-title><source>Cancer Res</source><volume>59</volume><fpage>2931</fpage><lpage>2938</lpage><?supplied-pmid 10383157?><pub-id pub-id-type="pmid">10383157</pub-id></element-citation></ref><ref id="b47-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soga</surname><given-names>S</given-names></name><name><surname>Sharma</surname><given-names>SV</given-names></name><name><surname>Shiotsu</surname><given-names>Y</given-names></name><name><surname>Shimizu</surname><given-names>M</given-names></name><name><surname>Tahara</surname><given-names>H</given-names></name><name><surname>Yamaguchi</surname><given-names>K</given-names></name><name><surname>Ikuina</surname><given-names>Y</given-names></name><name><surname>Murakata</surname><given-names>C</given-names></name><name><surname>Tamaoki</surname><given-names>T</given-names></name><name><surname>Kurebayashi</surname><given-names>J</given-names></name><name><surname>Schulte</surname><given-names>TW</given-names></name><name><surname>Neckers</surname><given-names>LM</given-names></name><name><surname>Akinaga</surname><given-names>S</given-names></name></person-group><year>2001</year><article-title>Stereospecific antitumor activity of radicicol oxime derivatives</article-title><source>Cancer Chemother Pharmacol</source><volume>48</volume><fpage>435</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1007/s002800100373</pub-id><pub-id pub-id-type="pmid">11800023</pub-id></element-citation></ref><ref id="b48-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Miao</surname><given-names>ZW</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>RY</given-names></name><name><surname>Zhang</surname><given-names>XD</given-names></name></person-group><year>2008</year><article-title>Synthesis and biological evaluation of novel naphthoquinone fused cyclic aminoalkylphosphonates and aminoalkylphosphonic monoester</article-title><source>Amino Acids</source><volume>35</volume><fpage>463</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1007/s00726-007-0570-8</pub-id><pub-id pub-id-type="pmid">17665273</pub-id></element-citation></ref><ref id="b49-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Leung</surname><given-names>CH</given-names></name><name><surname>Ma</surname><given-names>DL</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Che</surname><given-names>CM</given-names></name></person-group><year>2010</year><article-title>Organoplatinum(II) complexes with nucleobase motifs as inhibitors of human topoisomerase II catalytic activity</article-title><source>Chem Asian J</source><volume>5</volume><fpage>2271</fpage><lpage>2280</lpage><pub-id pub-id-type="doi">10.1002/asia.201000451</pub-id><?supplied-pmid 20730852?><pub-id pub-id-type="pmid">20730852</pub-id></element-citation></ref><ref id="b50-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>H</given-names></name><name><surname>Ruthenburg</surname><given-names>AJ</given-names></name><name><surname>Bechis</surname><given-names>SK</given-names></name><name><surname>Verdine</surname><given-names>GL</given-names></name></person-group><year>2005</year><article-title>Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase</article-title><source>J Biol Chem</source><volume>280</volume><fpage>37041</fpage><lpage>37047</lpage><pub-id pub-id-type="doi">10.1074/jbc.M506520200</pub-id><?supplied-pmid 16100112?><pub-id pub-id-type="pmid">16100112</pub-id></element-citation></ref><ref id="b51-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>XL</given-names></name><name><surname>Bao</surname><given-names>QC</given-names></name><name><surname>Jia</surname><given-names>JM</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Guo</surname><given-names>XK</given-names></name><name><surname>Zhang</surname><given-names>MY</given-names></name><name><surname>Wei</surname><given-names>JL</given-names></name><name><surname>Lu</surname><given-names>MC</given-names></name><name><surname>Xu</surname><given-names>LL</given-names></name><name><surname>Zhang</surname><given-names>XJ</given-names></name><name><surname>You</surname><given-names>QD</given-names></name><name><surname>Sun</surname><given-names>HP</given-names></name></person-group><year>2016</year><article-title>CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells</article-title><source>Sci Rep</source><volume>6</volume><year>1900</year><fpage>4</fpage><pub-id pub-id-type="doi">10.1038/srep19004</pub-id></element-citation></ref><ref id="b52-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>SY</given-names></name><name><surname>Jia</surname><given-names>XZ</given-names></name><name><surname>Feng</surname><given-names>LY</given-names></name><name><surname>Li</surname><given-names>SY</given-names></name><name><surname>An</surname><given-names>GS</given-names></name><name><surname>Ni</surname><given-names>JH</given-names></name><name><surname>Jia</surname><given-names>HT</given-names></name></person-group><year>2009</year><article-title>Inhibition of topoisomerase ii by 8-chloro-adenosine triphosphate induces DNA double-stranded breaks in 8-chloro-adenosine-exposed human myelocytic leukemia K562 cells</article-title><source>Biochem Pharmacol</source><volume>77</volume><fpage>433</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2008.10.022</pub-id><pub-id pub-id-type="pmid">19014910</pub-id></element-citation></ref><ref id="b53-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>ZQ</given-names></name><name><surname>Geng</surname><given-names>X</given-names></name><name><surname>Solit</surname><given-names>D</given-names></name><name><surname>Pratilas</surname><given-names>CA</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name><name><surname>Danishefsky</surname><given-names>SJ</given-names></name></person-group><year>2004</year><article-title>New efficient synthesis of resorcinylic macrolides via ynolides: Establishment of cycloproparadicicol as synthetically feasible preclinical anticancer agent based on Hsp90 as the target</article-title><source>J Am Chem Soc</source><volume>126</volume><fpage>7881</fpage><lpage>7889</lpage><pub-id pub-id-type="doi">10.1021/ja0484348</pub-id><?supplied-pmid 15212536?><pub-id pub-id-type="pmid">15212536</pub-id></element-citation></ref><ref id="b54-bt-24-453"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Q</given-names></name><name><surname>Weigel</surname><given-names>B</given-names></name><name><surname>Kersey</surname><given-names>J</given-names></name></person-group><year>2007</year><article-title>Synergism between etoposide and 17-AAG in leukemia cells: Critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51</article-title><source>Clin Cancer Res</source><volume>13</volume><fpage>1591</fpage><lpage>1600</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-1750</pub-id><?supplied-pmid 17332306?><pub-id pub-id-type="pmid">17332306</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-bt-24-453" orientation="portrait" position="float"><label>Fig. 1.</label><caption><p>The sequence alignment of the ATPase domain of topo II (1ZXM) and Hsp90 (3EKR). The alignment were generated using BioEdit.</p></caption><graphic xlink:href="bt-24-453f1"/></fig><fig id="f2-bt-24-453" orientation="portrait" position="float"><label>Fig. 2.</label><caption><p>The structure of ATPase domain of (A) topo II and (B) Hsp90. AMPPNP and ADP bound to topo II and Hsp90, respectively are represented in space-filling model colored by atom type (gray: carbon; red: oxygen; blue: nitrogen; orange: phosphorus). The proteins are represented in ribbon.</p></caption><graphic xlink:href="bt-24-453f2"/></fig><fig id="f3-bt-24-453" orientation="portrait" position="float"><label>Fig. 3.</label><caption><p>The comparison of ATP binding site of (A) topo II and (B) Hsp90. The channel was created using MOLCAD implemented in Sybyl, colored by electrostatic potential. The color ramp ranges from red (most positive) to purple (most negative). AMPPNP and ADP bound to topo II and Hsp90, respectively are represented in sticks colored by atom type (gray: carbon; red: oxygen; blue: nitrogen; orange: phosphorus). The proteins are represented in ribbon (blue: &#x003b2;-strand; red: &#x003b1;-helix).</p></caption><graphic xlink:href="bt-24-453f3"/></fig><fig id="f4-bt-24-453" orientation="portrait" position="float"><label>Fig. 4.</label><caption><p>The docking result of the selected inhibitors against topo II. The ATP binding site of topo II with inhibitors (A) PU3, (B) 3t, (C) AUY922 and (D) Comp. 14. The ligands are represented in sticks colored by atom type (magenta: carbon; red: oxygen; blue: nitrogen; orange: phosphorus) and the residues involved in hydrogen bonds are shown in dotted line colored in cyan.</p></caption><graphic xlink:href="bt-24-453f4"/></fig><fig id="f5-bt-24-453" orientation="portrait" position="float"><label>Fig. 5.</label><caption><p>The docking result of the selected inhibitors against Hsp90. The ATP binding site of topo II with inhibitors (A) PU3, (B) 3t, (C) AUY922, and (D) Comp.14. The ligands are represented in sticks colored by atom type (yellow: carbon; red: oxygen; blue: nitrogen; orange: phosphorus) and the residues involved in hydrogen bonds are shown in dotted line colored in cyan.</p></caption><graphic xlink:href="bt-24-453f5"/></fig><fig id="f6-bt-24-453" orientation="portrait" position="float"><label>Fig. 6.</label><caption><p>The pharmacophore model 2 generated from GASP. The pharmacophore features are two hydrophobic regions (HY, cyan), one acceptor atom (AA, green) and one donor site (DS, green) with PU3 as the template represented in sticks colored by atom type (gray: carbon; light blue: hydrogen; red: oxygen; blue: nitrogen; orange: phosphorus).</p></caption><graphic xlink:href="bt-24-453f6"/></fig><table-wrap id="t1-bt-24-453" orientation="portrait" position="float"><label>Table 1.</label><caption><p>The characterization of the active sites of topo II and Hsp90 by CASTp</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" rowspan="3" align="center" colspan="1">Protein</th><th colspan="2" valign="middle" align="center" rowspan="1">Pocket</th><th colspan="3" valign="middle" align="center" rowspan="1">Mouth</th></tr><tr><th colspan="2" valign="middle" align="center" rowspan="1">
<hr/></th><th colspan="3" valign="middle" align="center" rowspan="1">
<hr/></th></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1">Area (&#x000c5;<sup>2</sup>)</th><th valign="middle" align="center" rowspan="1" colspan="1">Volume (&#x000c5;<sup>3</sup>)</th><th valign="middle" align="center" rowspan="1" colspan="1">Number<xref rid="tfn1-bt-24-453" ref-type="table-fn">*</xref></th><th valign="middle" align="center" rowspan="1" colspan="1">Area (&#x000c5;<sup>2</sup>)</th><th valign="middle" align="center" rowspan="1" colspan="1">Circumcircle (&#x000c5;)</th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">792.2</td><td valign="middle" align="right" rowspan="1" colspan="1">1077.6</td><td valign="middle" align="center" rowspan="1" colspan="1">2</td><td valign="middle" align="right" rowspan="1" colspan="1">70.9</td><td valign="middle" align="center" rowspan="1" colspan="1">52.6</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">628.9</td><td valign="middle" align="right" rowspan="1" colspan="1">971.0</td><td valign="middle" align="center" rowspan="1" colspan="1">1</td><td valign="middle" align="right" rowspan="1" colspan="1">167.6</td><td valign="middle" align="center" rowspan="1" colspan="1">78.6</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-bt-24-453"><label>*</label><p>Number of mouth openings for the pocket. Each has to be large enough to allow the solvent probe to pass through.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-bt-24-453" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Topo II inhibitors that bind to the ATPase domain</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Name</th><th valign="middle" align="center" rowspan="1" colspan="1">Structure</th><th valign="middle" align="center" rowspan="1" colspan="1">IC<sub>50</sub><xref rid="tfn2-bt-24-453" ref-type="table-fn">*</xref></th><th valign="middle" align="center" rowspan="1" colspan="1">Type</th><th valign="middle" align="center" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Comp. 1</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i1.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1">1.7 &#x000b5;M</td><td valign="top" align="left" rowspan="1" colspan="1">Purine analog</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b11-bt-24-453" ref-type="bibr">Furet <italic>et al</italic>., 2009</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Comp. 2</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i2.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1">8.4 &#x000b5;M</td><td valign="top" align="left" rowspan="1" colspan="1">Purine analog</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b11-bt-24-453" ref-type="bibr">Furet <italic>et al</italic>., 2009</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NSC35866</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i3.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1">50 &#x000b5;M</td><td valign="top" align="left" rowspan="1" colspan="1">Purine analog</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b19-bt-24-453" ref-type="bibr">Jensen <italic>et al</italic>., 2005</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NCS348400</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i4.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1">0.39 &#x000b5;M</td><td valign="top" align="left" rowspan="1" colspan="1">Purine analog</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b18-bt-24-453" ref-type="bibr">Jensen <italic>et al</italic>., 2006</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">QAP1</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i5.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1">128 nM</td><td valign="top" align="left" rowspan="1" colspan="1">Purine analog</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b7-bt-24-453" ref-type="bibr">Chene <italic>et al</italic>., 2009</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2c</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i6.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1">K<sub>i</sub>=1.25 &#x000b5;M in ATP competition assay</td><td valign="top" align="left" rowspan="1" colspan="1">Purine analog with platinum</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b49-bt-24-453" ref-type="bibr">Wang <italic>et al</italic>., 2010</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">8-Cl-ATP</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i7.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b52-bt-24-453" ref-type="bibr">Yang <italic>et al</italic>., 2009</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3t</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i8.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">1,3-benzoazolyl-substituted pyrrolo[2,3-b]pyrazine derivatives</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b26-bt-24-453" ref-type="bibr">Li <italic>et al</italic>., 2016</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Daurinol</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i9.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Natural product</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b49-bt-24-453" ref-type="bibr">Wang <italic>et al</italic>., 2010</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TSC24</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i10.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1">K<sub>d</sub>=18.3 &#x000b5;M compared to ATP (615 &#x000b5;M)</td><td valign="top" align="left" rowspan="1" colspan="1">Thiosemicarbazone</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b15-bt-24-453" ref-type="bibr">Huang <italic>et al</italic>., 2010</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Comp. 5</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i11.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1">52.77 &#x000b5;M, K<sub>i</sub>=75 &#x000b5;M</td><td valign="top" align="left" rowspan="1" colspan="1">N-fused imidazole</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b4-bt-24-453" ref-type="bibr">Baviskar <italic>et al</italic>., 2011</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Comp. 14</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i12.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Xanthone</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b22-bt-24-453" ref-type="bibr">Jun <italic>et al</italic>., 2011</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Comp. 14mod</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i13.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Xanthone</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b36-bt-24-453" ref-type="bibr">Park <italic>et al</italic>., 2013</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Comp. 18</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i14.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Naphthoquinone fused cyclic aminoalkyl-phosphonates and aminoalkyl-phosphonic monoester</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b49-bt-24-453" ref-type="bibr">Wang <italic>et al</italic>., 2008</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Salvicine</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i15.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1">K<sub>d</sub>=74.3 &#x000b5;M</td><td valign="top" align="left" rowspan="1" colspan="1">Natural product</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b14-bt-24-453" ref-type="bibr">Hu <italic>et al</italic>., 2006</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">D11</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i16.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1">K<sub>d</sub>=37.7 &#x000b5;M</td><td valign="top" align="left" rowspan="1" colspan="1">Diphyllin glycoside</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b12-bt-24-453" ref-type="bibr">Gui <italic>et al</italic>., 2011</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gambogic acid</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i17.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1">K<sub>d</sub>=3.32 &#x000b5;M</td><td valign="top" align="left" rowspan="1" colspan="1">Natural product</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b41-bt-24-453" ref-type="bibr">Qin <italic>et al</italic>., 2007</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Emodin</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i18.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Anthraquinone analog</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b27-bt-24-453" ref-type="bibr">Li <italic>et al</italic>., 2010</xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn2-bt-24-453"><label>*</label><p>IC<sub>50</sub> values for the compound otherwise noted; inhibition constant (K<sub>i</sub>), dissociation constant (K<sub>d</sub>).</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-bt-24-453" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Hsp90 inhibitors that bind to the ATPase domain</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1">Name</th><th valign="middle" align="center" rowspan="1" colspan="1">Structure</th><th valign="middle" align="center" rowspan="1" colspan="1">IC<sub>50</sub></th><th valign="middle" align="center" rowspan="1" colspan="1">Type</th><th valign="middle" align="center" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">GDA</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i19.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1">K<sub>d</sub>=1.2 &#x000b5;M (determined from isothermal calorimetry (ITC))</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b42-bt-24-453" ref-type="bibr">Roe <italic>et al</italic>., 1999</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Radicicol</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i20.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1">23 nM, K<sub>d</sub>=19 nM (ITC)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b42-bt-24-453" ref-type="bibr">Roe <italic>et al</italic>., 1999</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">17-AAG</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i21.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Geldanamycin derivative</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b44-bt-24-453" ref-type="bibr">Schulte and Neckers, 1998</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">17-DMAG</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i22.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Geldanamycin derivative</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b20-bt-24-453" ref-type="bibr">Jez <italic>et al</italic>., 2003</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">KOSN1559</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i23.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1">K<sub>d</sub>=16 nM</td><td valign="top" align="left" rowspan="1" colspan="1">Geldanamycin derivative</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b37-bt-24-453" ref-type="bibr">Patel <italic>et al</italic>., 2004</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">KF25706</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i24.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">RDC analog</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b46-bt-24-453" ref-type="bibr">Soga <italic>et al</italic>., 1999</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">KF29163</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i25.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">RDC analog</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b1-bt-24-453" ref-type="bibr">Agatsuma <italic>et al</italic>., 2002</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">c-RDC</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i26.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">RDC analog</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b53-bt-24-453" ref-type="bibr">Yang <italic>et al</italic>., 2004</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Aigialmycin D</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i27.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">RDC analog</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b53-bt-24-453" ref-type="bibr">Yang <italic>et al</italic>., 2004</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pochonin A</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i28.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1">90 nM</td><td valign="top" align="left" rowspan="1" colspan="1">RDC analog</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b30-bt-24-453" ref-type="bibr">Moulin <italic>et al</italic>., 2005a</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pochonin D</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i29.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">RDC analog</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b31-bt-24-453" ref-type="bibr">Moulin <italic>et al</italic>., 2005b</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">KF58333</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i30.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">RDC analog</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b46-bt-24-453" ref-type="bibr">Soga <italic>et al</italic>., 2001</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">o-(piperidinocarbonyl) methyloxime derivative of RDC</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i31.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">RDC analog</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b16-bt-24-453" ref-type="bibr">Ikuina <italic>et al</italic>., 2003</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PU3</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i32.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1">K<sub>d</sub>=15&#x0223c;20 &#x000b5;M</td><td valign="top" align="left" rowspan="1" colspan="1">Purine derivative</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b8-bt-24-453" ref-type="bibr">Chiosis <italic>et al</italic>., 2001</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PU3</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i33.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1">K<sub>d</sub>=15&#x0223c;20 &#x000b5;M</td><td valign="top" align="left" rowspan="1" colspan="1">Purine derivative</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b8-bt-24-453" ref-type="bibr">Chiosis <italic>et al</italic>., 2001</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CCT018159</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i34.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1">8.9 &#x000b5;M</td><td valign="top" align="left" rowspan="1" colspan="1">Pyrazole</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b43-bt-24-453" ref-type="bibr">Rowlands <italic>et al</italic>., 2004</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">G3130</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i35.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1">K<sub>d</sub> =280 nM (SPR)</td><td valign="top" align="left" rowspan="1" colspan="1">Pyrazole</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b24-bt-24-453" ref-type="bibr">Kreusch <italic>et al</italic>., 2005</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SNX0723</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i36.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Benzamide</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b40-bt-24-453" ref-type="bibr">Putcha <italic>et al</italic>., 2010</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AUY922</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i37.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Resorcinol</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b5-bt-24-453" ref-type="bibr">Brough <italic>et al</italic>., 2008</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AT-13387</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i38.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Resorcinol</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b32-bt-24-453" ref-type="bibr">Murray <italic>et al</italic>., 2010</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CPUY201112</td><td valign="top" align="left" rowspan="1" colspan="1">
<inline-graphic xlink:href="bt-24-453i39.jpg"/></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Resorcinol</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="b51-bt-24-453" ref-type="bibr">Xu <italic>et al</italic>., 2016</xref></td></tr></tbody></table></table-wrap><table-wrap id="t4-bt-24-453" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Topo II docking results of combined inhibitors</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" align="center" rowspan="1" colspan="1">Name</th><th valign="bottom" align="center" rowspan="1" colspan="1">Target</th><th valign="bottom" align="center" rowspan="1" colspan="1">Total Score<xref rid="tfn3-bt-24-453" ref-type="table-fn"><sup>1</sup></xref></th><th valign="bottom" align="center" rowspan="1" colspan="1">Crash<xref rid="tfn4-bt-24-453" ref-type="table-fn"><sup>2</sup></xref></th><th valign="bottom" align="center" rowspan="1" colspan="1">Polar<xref rid="tfn5-bt-24-453" ref-type="table-fn"><sup>3</sup></xref></th><th valign="bottom" align="center" rowspan="1" colspan="1">Similarity<xref rid="tfn6-bt-24-453" ref-type="table-fn"><sup>4</sup></xref></th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">PU3</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">13.1154</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;0.9961</td><td valign="middle" align="center" rowspan="1" colspan="1">4.5667</td><td valign="middle" align="center" rowspan="1" colspan="1">0.541</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">8-Cl-ATP</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">11.2764</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;2.0944</td><td valign="middle" align="center" rowspan="1" colspan="1">11.0551</td><td valign="middle" align="center" rowspan="1" colspan="1">0.527</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">3t</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">10.4766</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;0.6886</td><td valign="middle" align="center" rowspan="1" colspan="1">1.7276</td><td valign="middle" align="center" rowspan="1" colspan="1">0.397</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Comp. 14mod</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">10.2868</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;2.5358</td><td valign="middle" align="center" rowspan="1" colspan="1">3.0286</td><td valign="middle" align="center" rowspan="1" colspan="1">0.407</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Comp. 14</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">9.927</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;2.1249</td><td valign="middle" align="center" rowspan="1" colspan="1">3.0481</td><td valign="middle" align="center" rowspan="1" colspan="1">0.427</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">AUY922</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">9.8884</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;3.5617</td><td valign="middle" align="center" rowspan="1" colspan="1">3.1905</td><td valign="middle" align="center" rowspan="1" colspan="1">0.463</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Salvicine R</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">8.5495</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;2.5071</td><td valign="middle" align="center" rowspan="1" colspan="1">2.9333</td><td valign="middle" align="center" rowspan="1" colspan="1">0.333</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">CCT018159</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">8.0916</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;0.9934</td><td valign="middle" align="center" rowspan="1" colspan="1">2.739</td><td valign="middle" align="center" rowspan="1" colspan="1">0.382</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">SNX0723</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">8.034</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;5.2877</td><td valign="middle" align="center" rowspan="1" colspan="1">2.8872</td><td valign="middle" align="center" rowspan="1" colspan="1">0.443</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">NSC348400</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">7.9712</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;3.1936</td><td valign="middle" align="center" rowspan="1" colspan="1">5.9702</td><td valign="middle" align="center" rowspan="1" colspan="1">0.568</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Comp. 2</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">7.9074</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;0.4726</td><td valign="middle" align="center" rowspan="1" colspan="1">2.1046</td><td valign="middle" align="center" rowspan="1" colspan="1">0.418</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Daurinol</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">7.564</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;1.1849</td><td valign="middle" align="center" rowspan="1" colspan="1">4.962</td><td valign="middle" align="center" rowspan="1" colspan="1">0.459</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Comp. 5</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">7.4758</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;1.6766</td><td valign="middle" align="center" rowspan="1" colspan="1">2.5831</td><td valign="middle" align="center" rowspan="1" colspan="1">0.404</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">QAP1</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">7.3683</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;2.2725</td><td valign="middle" align="center" rowspan="1" colspan="1">2.9142</td><td valign="middle" align="center" rowspan="1" colspan="1">0.372</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">G3130</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">7.1866</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;0.3941</td><td valign="middle" align="center" rowspan="1" colspan="1">3.5543</td><td valign="middle" align="center" rowspan="1" colspan="1">0.336</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Comp. 1</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">7.1634</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;1.3298</td><td valign="middle" align="center" rowspan="1" colspan="1">3.7455</td><td valign="middle" align="center" rowspan="1" colspan="1">0.235</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Salvicine S</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">7.0436</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;2.892</td><td valign="middle" align="center" rowspan="1" colspan="1">3.1112</td><td valign="middle" align="center" rowspan="1" colspan="1">0.461</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">NSC35866</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">6.9393</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;1.0221</td><td valign="middle" align="center" rowspan="1" colspan="1">2.0358</td><td valign="middle" align="center" rowspan="1" colspan="1">0.458</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">KF58333</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">6.7973</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;4.5147</td><td valign="middle" align="center" rowspan="1" colspan="1">2.4482</td><td valign="middle" align="center" rowspan="1" colspan="1">0.380</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">CPUY201112</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">6.7935</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;2.242</td><td valign="middle" align="center" rowspan="1" colspan="1">1.4817</td><td valign="middle" align="center" rowspan="1" colspan="1">0.528</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">AT13387</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">6.2906</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;9.1331</td><td valign="middle" align="center" rowspan="1" colspan="1">4.0913</td><td valign="middle" align="center" rowspan="1" colspan="1">0.415</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Emodin</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">6.279</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;0.6391</td><td valign="middle" align="center" rowspan="1" colspan="1">3.2784</td><td valign="middle" align="center" rowspan="1" colspan="1">0.440</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">2c</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">5.9724</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;5.5461</td><td valign="middle" align="center" rowspan="1" colspan="1">0.0714</td><td valign="middle" align="center" rowspan="1" colspan="1">0.342</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Pochonin D</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">5.8197</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;3.0107</td><td valign="middle" align="center" rowspan="1" colspan="1">1.6854</td><td valign="middle" align="center" rowspan="1" colspan="1">0.406</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">o-RDC</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">5.743</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;6.3103</td><td valign="middle" align="center" rowspan="1" colspan="1">1.714</td><td valign="middle" align="center" rowspan="1" colspan="1">0.393</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Pochonin A</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">5.6544</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;3.0449</td><td valign="middle" align="center" rowspan="1" colspan="1">1.7182</td><td valign="middle" align="center" rowspan="1" colspan="1">0.431</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">c-RDC</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">5.571</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;3.8203</td><td valign="middle" align="center" rowspan="1" colspan="1">2.7142</td><td valign="middle" align="center" rowspan="1" colspan="1">0.353</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Comp. 18</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">5.2181</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;0.9817</td><td valign="middle" align="center" rowspan="1" colspan="1">2.1991</td><td valign="middle" align="center" rowspan="1" colspan="1">0.381</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">KF25706</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">4.9578</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;3.5256</td><td valign="middle" align="center" rowspan="1" colspan="1">2.2759</td><td valign="middle" align="center" rowspan="1" colspan="1">0.467</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">KF29163</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">4.8178</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;2.5315</td><td valign="middle" align="center" rowspan="1" colspan="1">2.4504</td><td valign="middle" align="center" rowspan="1" colspan="1">0.406</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">RDC</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">4.2342</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;2.6456</td><td valign="middle" align="center" rowspan="1" colspan="1">1.1539</td><td valign="middle" align="center" rowspan="1" colspan="1">0.421</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Aigialomycin D</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">4.1481</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;4.3331</td><td valign="middle" align="center" rowspan="1" colspan="1">4.1964</td><td valign="middle" align="center" rowspan="1" colspan="1">0.433</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">TSC24</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">4.1158</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;0.8441</td><td valign="middle" align="center" rowspan="1" colspan="1">0.0514</td><td valign="middle" align="center" rowspan="1" colspan="1">0.392</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Gambogic acid</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">3.8992</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;7.3216</td><td valign="middle" align="center" rowspan="1" colspan="1">0.844</td><td valign="middle" align="center" rowspan="1" colspan="1">0.385</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">D11</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;1.4678</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;14.195</td><td valign="middle" align="center" rowspan="1" colspan="1">1.1678</td><td valign="middle" align="center" rowspan="1" colspan="1">0.361</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">KOSN1559</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;2.5462</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;14.8183</td><td valign="middle" align="center" rowspan="1" colspan="1">2.1768</td><td valign="middle" align="center" rowspan="1" colspan="1">0.428</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">GDM</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;4.9652</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;18.4653</td><td valign="middle" align="center" rowspan="1" colspan="1">2.1288</td><td valign="middle" align="center" rowspan="1" colspan="1">0.358</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">17-AAG</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;6.3308</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;17.5419</td><td valign="middle" align="center" rowspan="1" colspan="1">0.7688</td><td valign="middle" align="center" rowspan="1" colspan="1">0.478</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">17-DMAG</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;8.4678</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;21.6041</td><td valign="middle" align="center" rowspan="1" colspan="1">1.4689</td><td valign="middle" align="center" rowspan="1" colspan="1">0.508</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-bt-24-453"><label>1</label><p>Total Score represents the total Surflex-Dock score expressed as &#x02013;log(<italic>K</italic><sub>d</sub>),</p></fn><fn id="tfn4-bt-24-453"><label>2</label><p>Crash is the degree of inappropriate penetration by the ligand into the protein between ligand atoms that are separated by rotatable bonds. Crash scores close to 0 are favorable,</p></fn><fn id="tfn5-bt-24-453"><label>3</label><p>Polar values show the contribution of the polar interactions to the total score,</p></fn><fn id="tfn6-bt-24-453"><label>4</label><p>Similarity indicates the difference between the top scoring pose and the original ligand (AMPPNP) used as the reference.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t5-bt-24-453" orientation="portrait" position="float"><label>Table 5.</label><caption><p>Hsp90 docking results of combined inhibitors</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" align="center" rowspan="1" colspan="1">Name</th><th valign="bottom" align="center" rowspan="1" colspan="1">Target</th><th valign="bottom" align="center" rowspan="1" colspan="1">Total Score</th><th valign="bottom" align="center" rowspan="1" colspan="1">Crash</th><th valign="bottom" align="center" rowspan="1" colspan="1">Polar</th><th valign="bottom" align="center" rowspan="1" colspan="1">Similarity</th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">AUY922</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">11.3281</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;2.9912</td><td valign="middle" align="center" rowspan="1" colspan="1">5.8905</td><td valign="middle" align="center" rowspan="1" colspan="1">0.566</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">KOSN1559</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">10.5386</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;4.2057</td><td valign="middle" align="center" rowspan="1" colspan="1">6.0038</td><td valign="middle" align="center" rowspan="1" colspan="1">0.497</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">GDM</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">9.0405</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;4.3587</td><td valign="middle" align="center" rowspan="1" colspan="1">5.7304</td><td valign="middle" align="center" rowspan="1" colspan="1">0.506</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">3t</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">8.9981</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;1.9006</td><td valign="middle" align="center" rowspan="1" colspan="1">2.2646</td><td valign="middle" align="center" rowspan="1" colspan="1">0.451</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">KF58333</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">8.8035</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;2.216</td><td valign="middle" align="center" rowspan="1" colspan="1">3.7782</td><td valign="middle" align="center" rowspan="1" colspan="1">0.475</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">PU3</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">8.6779</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;1.3914</td><td valign="middle" align="center" rowspan="1" colspan="1">2.3162</td><td valign="middle" align="center" rowspan="1" colspan="1">0.465</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Comp. 14</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">8.0945</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;2.9386</td><td valign="middle" align="center" rowspan="1" colspan="1">4.3295</td><td valign="middle" align="center" rowspan="1" colspan="1">0.547</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">o-RDC</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">7.4652</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;3.5968</td><td valign="middle" align="center" rowspan="1" colspan="1">3.1916</td><td valign="middle" align="center" rowspan="1" colspan="1">0.421</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">CCT018159</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">7.4339</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;0.7895</td><td valign="middle" align="center" rowspan="1" colspan="1">3.2601</td><td valign="middle" align="center" rowspan="1" colspan="1">0.521</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">SNX0723</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">7.1997</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;2.4905</td><td valign="middle" align="center" rowspan="1" colspan="1">1.3399</td><td valign="middle" align="center" rowspan="1" colspan="1">0.526</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Salvicine S</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">7.1362</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;1.4093</td><td valign="middle" align="center" rowspan="1" colspan="1">1.6745</td><td valign="middle" align="center" rowspan="1" colspan="1">0.475</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">AT13387</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">7.1259</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;2.0725</td><td valign="middle" align="center" rowspan="1" colspan="1">1.7217</td><td valign="middle" align="center" rowspan="1" colspan="1">0.519</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Comp. 14mod</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">7.0102</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;2.3685</td><td valign="middle" align="center" rowspan="1" colspan="1">3.184</td><td valign="middle" align="center" rowspan="1" colspan="1">0.519</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">G3130</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">6.8551</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;0.5655</td><td valign="middle" align="center" rowspan="1" colspan="1">4.089</td><td valign="middle" align="center" rowspan="1" colspan="1">0.514</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">QAP1</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">6.7837</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;2.2874</td><td valign="middle" align="center" rowspan="1" colspan="1">0.9711</td><td valign="middle" align="center" rowspan="1" colspan="1">0.497</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">CPUY201112</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">6.7467</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;2.5928</td><td valign="middle" align="center" rowspan="1" colspan="1">2.7711</td><td valign="middle" align="center" rowspan="1" colspan="1">0.612</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">NSC348400</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">6.7386</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;1.4421</td><td valign="middle" align="center" rowspan="1" colspan="1">3.7083</td><td valign="middle" align="center" rowspan="1" colspan="1">0.511</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">RDC</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">6.6884</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;2.5576</td><td valign="middle" align="center" rowspan="1" colspan="1">3.4177</td><td valign="middle" align="center" rowspan="1" colspan="1">0.666</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">NSC35866</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">6.649</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;1.1619</td><td valign="middle" align="center" rowspan="1" colspan="1">2.6058</td><td valign="middle" align="center" rowspan="1" colspan="1">0.486</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Salvicine R</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">6.4918</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;2.4288</td><td valign="middle" align="center" rowspan="1" colspan="1">2.1968</td><td valign="middle" align="center" rowspan="1" colspan="1">0.510</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Comp. 1</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">6.4641</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;1.627</td><td valign="middle" align="center" rowspan="1" colspan="1">2.2857</td><td valign="middle" align="center" rowspan="1" colspan="1">0.561</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">2c</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">6.4036</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;3.4089</td><td valign="middle" align="center" rowspan="1" colspan="1">0.0014</td><td valign="middle" align="center" rowspan="1" colspan="1">0.329</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">KF25706</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">6.185</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;2.8315</td><td valign="middle" align="center" rowspan="1" colspan="1">3.6404</td><td valign="middle" align="center" rowspan="1" colspan="1">0.647</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Gambogic acid</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">6.0092</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;2.2055</td><td valign="middle" align="center" rowspan="1" colspan="1">1.3905</td><td valign="middle" align="center" rowspan="1" colspan="1">0.297</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Comp. 2</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">5.952</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;1.2823</td><td valign="middle" align="center" rowspan="1" colspan="1">1.4835</td><td valign="middle" align="center" rowspan="1" colspan="1">0.524</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Daurinol</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">5.8292</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;0.4604</td><td valign="middle" align="center" rowspan="1" colspan="1">1.3936</td><td valign="middle" align="center" rowspan="1" colspan="1">0.556</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">KF29163</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">5.7498</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;2.3134</td><td valign="middle" align="center" rowspan="1" colspan="1">1.6213</td><td valign="middle" align="center" rowspan="1" colspan="1">0.530</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">17-DMAG</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">5.718</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;3.6373</td><td valign="middle" align="center" rowspan="1" colspan="1">1.0756</td><td valign="middle" align="center" rowspan="1" colspan="1">0.318</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">c-RDC</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">5.6849</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;3.5861</td><td valign="middle" align="center" rowspan="1" colspan="1">3.0525</td><td valign="middle" align="center" rowspan="1" colspan="1">0.691</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Comp. 5</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">5.6657</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;1.6574</td><td valign="middle" align="center" rowspan="1" colspan="1">1.9241</td><td valign="middle" align="center" rowspan="1" colspan="1">0.430</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">D11</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">5.6512</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;0.8901</td><td valign="middle" align="center" rowspan="1" colspan="1">2.5246</td><td valign="middle" align="center" rowspan="1" colspan="1">0.390</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Emodin</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">5.6113</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;0.429</td><td valign="middle" align="center" rowspan="1" colspan="1">1.9987</td><td valign="middle" align="center" rowspan="1" colspan="1">0.398</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">8-Cl-ATP</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">5.5933</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;1.2132</td><td valign="middle" align="center" rowspan="1" colspan="1">4.7994</td><td valign="middle" align="center" rowspan="1" colspan="1">0.399</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Pochonin D</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">5.5041</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;1.5103</td><td valign="middle" align="center" rowspan="1" colspan="1">2.1344</td><td valign="middle" align="center" rowspan="1" colspan="1">0.550</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">TSC24</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">5.477</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;1.2353</td><td valign="middle" align="center" rowspan="1" colspan="1">0.5795</td><td valign="middle" align="center" rowspan="1" colspan="1">0.418</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Pochonin A</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">5.4494</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;1.3695</td><td valign="middle" align="center" rowspan="1" colspan="1">2.6113</td><td valign="middle" align="center" rowspan="1" colspan="1">0.279</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">17-AAG</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">5.2911</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;2.6657</td><td valign="middle" align="center" rowspan="1" colspan="1">0.545</td><td valign="middle" align="center" rowspan="1" colspan="1">0.301</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Aigialomycin D</td><td valign="middle" align="center" rowspan="1" colspan="1">Hsp90</td><td valign="middle" align="center" rowspan="1" colspan="1">4.8757</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;3.236</td><td valign="middle" align="center" rowspan="1" colspan="1">3.4461</td><td valign="middle" align="center" rowspan="1" colspan="1">0.549</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Comp. 18</td><td valign="middle" align="center" rowspan="1" colspan="1">Topo II</td><td valign="middle" align="center" rowspan="1" colspan="1">4.553</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02212;0.4098</td><td valign="middle" align="center" rowspan="1" colspan="1">0.9114</td><td valign="middle" align="center" rowspan="1" colspan="1">0.427</td></tr></tbody></table></table-wrap><table-wrap id="t6-bt-24-453" orientation="portrait" position="float"><label>Table 6.</label><caption><p>Docking analysis of selected inhibitors</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="3" valign="middle" align="center" rowspan="1">Topo II</th><th colspan="3" valign="middle" align="center" rowspan="1">Hsp90</th></tr><tr><th colspan="3" valign="middle" align="center" rowspan="1">
<hr/></th><th colspan="3" valign="middle" align="center" rowspan="1">
<hr/></th></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1">Name</th><th valign="middle" align="center" rowspan="1" colspan="1">Hydrophobic</th><th valign="middle" align="center" rowspan="1" colspan="1">Hydrogen bonding</th><th valign="middle" align="center" rowspan="1" colspan="1">Name</th><th valign="middle" align="center" rowspan="1" colspan="1">Hydrophobic</th><th valign="middle" align="center" rowspan="1" colspan="1">Hydrogen bonding</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">PU3</td><td valign="top" align="left" rowspan="1" colspan="1">Asn91, Asp94, Arg98, Asn120, Ile125, Ile141, Phe142, Ser149, Asn150, Thr159, Gly161, Arg162, Gly164, Ala167, Lys168, Thr215</td><td valign="top" align="left" rowspan="1" colspan="1">Asn91, Asn120, Ala167, Thr215</td><td valign="top" align="left" rowspan="1" colspan="1">PU3</td><td valign="top" align="left" rowspan="1" colspan="1">Asn51, Asp54, Ala55, Asp93, Ile96, Gly97, Met98, Asn106, Leu107, Gly135, Val136, Phe138, Val150, Thr184, Val186</td><td valign="top" align="left" rowspan="1" colspan="1">Asp54, Thr184</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3t</td><td valign="top" align="left" rowspan="1" colspan="1">Asn91, Ala92, Asn95, Asn120, Pro126, Ile141, Phe142, Ser149, Gly164, Tyr165, Gly166, Ala167, Lys168, Thr215, Ile217</td><td valign="top" align="left" rowspan="1" colspan="1">Asn91</td><td valign="top" align="left" rowspan="1" colspan="1">3t</td><td valign="top" align="left" rowspan="1" colspan="1">Asn51, Ala55, Lys58, Ile96, Gly97, Met98, Asn106, Phe138, Val150, His154, Thr184, Val186</td><td valign="top" align="left" rowspan="1" colspan="1">Lys58, Gly97</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Comp. 14</td><td valign="top" align="left" rowspan="1" colspan="1">Ile88, Asn91, Ala92, Asp94, Asn95, Ile118, Asn120, Ile125, Asn150, Gly161, Gly164, Tyr165, Ala167, Lys168, Thr215, Ile217</td><td valign="top" align="left" rowspan="1" colspan="1">Asp94, Thr215</td><td valign="top" align="left" rowspan="1" colspan="1">Comp. 14</td><td valign="top" align="left" rowspan="1" colspan="1">Asn51, Ser52, Ala55, Asp93, Ile96, Gly97, Met98, Asn106, Phe138, Val150, Thr184, Val186</td><td valign="top" align="left" rowspan="1" colspan="1">Asp93, Gly97, Thr184</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AUY922</td><td valign="top" align="left" rowspan="1" colspan="1">Ile88, Asn91, Ala92, Asn95, Arg98, Ile118, Asn120, Ile125, Pro126, Ile141, Phe142, Ser149, Asn150, Gly161, Gly164, Tyr165, Gly166, Ala167, Lys168, Thr215, Ile217</td><td valign="top" align="left" rowspan="1" colspan="1">Asn95, Asn120, Ser149</td><td valign="top" align="left" rowspan="1" colspan="1">AUY922</td><td valign="top" align="left" rowspan="1" colspan="1">Asn51, Ala55, Lys58, Asp93, Ile96, Gly97, Met98, Asp102, Leu107, Gly135, ValL136, Gly137, Phe138, Val150, Thr184, Val186</td><td valign="top" align="left" rowspan="1" colspan="1">Asn51, Lys58, Asp93, Gly97, Phe138</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">8-Cl-ATP</td><td valign="top" align="left" rowspan="1" colspan="1">Asn91, Asp94, Asn95, Arg98, Lys123, Gly124, Ile125, Ser149, Asn150, Gly161, Arg162, Asn163, Gly164, Tyr165, Gly166, Ala167, Gln376, Lys378</td><td valign="top" align="left" rowspan="1" colspan="1">Asn91, Asp94, Asn150, Arg162, Tyr165, Gly166, Lys378</td><td valign="top" align="left" rowspan="1" colspan="1">KOSN1599</td><td valign="top" align="left" rowspan="1" colspan="1">Asn51, Ser52, Asp54, Ala55, Lys58, Asp93, Ile96, Met98, ASP102, Asn106, Leu107, Phe138, Thr184, Val186</td><td valign="top" align="left" rowspan="1" colspan="1">Ser52, Asp54, Phe138</td></tr></tbody></table></table-wrap><table-wrap id="t7-bt-24-453" orientation="portrait" position="float"><label>Table 7.</label><caption><p>Results of pharmacophore hypothesis generated by GASP</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" align="center" rowspan="1" colspan="1">Model</th><th valign="bottom" align="center" rowspan="1" colspan="1">Fitness</th><th valign="bottom" align="center" rowspan="1" colspan="1">Size<xref rid="tfn7-bt-24-453" ref-type="table-fn"><sup>a</sup></xref></th><th valign="bottom" align="center" rowspan="1" colspan="1">Hits<xref rid="tfn8-bt-24-453" ref-type="table-fn"><sup>b</sup></xref></th><th valign="bottom" align="center" rowspan="1" colspan="1">Dmean<xref rid="tfn9-bt-24-453" ref-type="table-fn"><sup>c</sup></xref></th><th valign="bottom" align="center" rowspan="1" colspan="1">Features<xref rid="tfn10-bt-24-453" ref-type="table-fn"><sup>d</sup></xref></th></tr></thead><tbody><tr><td valign="middle" align="center" rowspan="1" colspan="1">1</td><td valign="middle" align="center" rowspan="1" colspan="1">2676.46</td><td valign="middle" align="center" rowspan="1" colspan="1">4</td><td valign="middle" align="center" rowspan="1" colspan="1">4</td><td valign="middle" align="center" rowspan="1" colspan="1">5.7693</td><td valign="middle" align="left" rowspan="1" colspan="1">DS, AA, HY1, HY2</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">2</td><td valign="middle" align="center" rowspan="1" colspan="1">2689.23</td><td valign="middle" align="center" rowspan="1" colspan="1">4</td><td valign="middle" align="center" rowspan="1" colspan="1">4</td><td valign="middle" align="center" rowspan="1" colspan="1">3.5916</td><td valign="middle" align="left" rowspan="1" colspan="1">DS, AA, HY1, HY2</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">3</td><td valign="middle" align="center" rowspan="1" colspan="1">2589.82</td><td valign="middle" align="center" rowspan="1" colspan="1">4</td><td valign="middle" align="center" rowspan="1" colspan="1">4</td><td valign="middle" align="center" rowspan="1" colspan="1">3.1774</td><td valign="middle" align="left" rowspan="1" colspan="1">DS, AA, HY1, HY2</td></tr><tr><td valign="middle" align="center" rowspan="1" colspan="1">4</td><td valign="middle" align="center" rowspan="1" colspan="1">2663.25</td><td valign="middle" align="center" rowspan="1" colspan="1">2</td><td valign="middle" align="center" rowspan="1" colspan="1">4</td><td valign="middle" align="center" rowspan="1" colspan="1">4.5547</td><td valign="middle" align="left" rowspan="1" colspan="1">HY1, HY2</td></tr></tbody></table><table-wrap-foot><fn id="tfn7-bt-24-453"><label>a</label><p>Number of features in the model,</p></fn><fn id="tfn8-bt-24-453"><label>b</label><p>Number of molecules that matched during the search,</p></fn><fn id="tfn9-bt-24-453"><label>c</label><p>Average interpoint distance,</p></fn><fn id="tfn10-bt-24-453"><label>d</label><p>Pharmacophore features. DS: donor site, AA: acceptor site, HY: hydrophobic.</p></fn></table-wrap-foot></table-wrap></floats-group></article>